Concentration device, method for concentrating specimen liquid, method for testing specimen liquid, and test kit

The concentration device with a superabsorbent polymer and porous membrane system rapidly concentrates sample liquids, improving sensitivity and suitability for on-site diagnostics through centrifugal force and immunochromatography.

JP7590441B2Active Publication Date: 2024-11-26FUJIFILM CORP
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2022547461
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-09-11
Filing Date
2021-08-18
Publication Date
2024-11-26
Estimated Expiration
2041-08-18

AI Technical Summary

Technical Problem

Conventional ultrafiltration methods for concentrating sample liquids, particularly for on-site diagnostics, are time-consuming and not suitable for rapid analysis.

Method used

A concentration device comprising a first container with a superabsorbent polymer and a second container, utilizing a porous membrane with specific pore sizes and materials, enables rapid concentration of sample liquids through centrifugal force, followed by detection using immunochromatography.

Benefits of technology

The device achieves rapid concentration of sample liquids in minutes, enhancing detection sensitivity and reducing the need for complex equipment, making it suitable for point-of-care testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590441000003
    Figure 0007590441000003
  • Figure 0007590441000004
    Figure 0007590441000004
  • Figure 0007590441000005
    Figure 0007590441000005
Patent Text Reader

Abstract

The present invention provides: a concentration device which is capable of concentrating a sample solution in a short period of time; a method for concentrating a sample solution, wherein a sample solution is concentrated with use of this concentration device; a method for texting a sample solution with use of this method for concentrating a sample solution; and a test kit which is provided with this concentration device and a detection device. A concentration device for concentrating a sample solution that is an aqueous solution containing a polymer that is contained in a biological fluid, said concentration device being provided with a first container in which a highly water-absorbent polymer is contained, and a second container. A part of the first container is composed of a discharge part that is configured from a porous membrane having pore diameters of from 0.05 μm to 10 μm; the highly water-absorbent polymer absorbs a solution contained in a sample solution that has been injected into the first container, thereby producing a sample solution concentrate within the first container, said sample solution concentrate being the concentrated solution of the sample solution; and the second container recovers the sample solution concentrate that is discharged from the discharge part.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a concentrating device, a method for concentrating a sample liquid, a method for testing a sample liquid, and a test kit. [Background technology]

[0002] 2. Description of the Related Art Conventionally, there is known a technique for concentrating an aqueous solution containing macromolecules contained in a biological fluid, such as an antigen (hereinafter also referred to as a "sample liquid"), using an ultrafiltration device (see, for example, Patent Document 1). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Special Publication No. 2013-527225 Summary of the Invention [Problem to be solved by the invention]

[0004] Recently, there is a demand for more sensitive immunoassay methods such as immunochromatography. In this context, the present inventors have investigated a method of concentrating a sample liquid using an ultrafiltration device and performing an immunoassay using the concentrated sample liquid. As a result, it has become clear that while this method does indeed improve sensitivity, concentrating a sample liquid using an ultrafiltration device takes time and is not suitable for point-of-care diagnosis (POCT).

[0005] Therefore, in consideration of the above-mentioned situation, the present invention aims to provide a concentrating device capable of concentrating a specimen liquid in a short period of time, a method for concentrating a specimen liquid using the concentrating device, a method for testing a specimen liquid using the method for concentrating a specimen liquid, and a test kit comprising the concentrating device and a detection device. [Means for solving the problem]

[0006] As a result of extensive investigation into the above problems, the present inventors have found that the above problems can be solved by the following configuration.

[0007] (1) A concentrating device for concentrating a specimen liquid which is an aqueous solution containing a macromolecule contained in a biological fluid, comprising: The device includes a first container containing a highly absorbent polymer and a second container, The first container is partly constituted by a discharge part made of a porous membrane having a pore size of 0.05 μm or more and 10 μm or less, the superabsorbent polymer absorbs a solution contained in the sample liquid poured into the first container, and generates a sample liquid concentrate in the first container, which is a concentrated solution of the sample liquid; The second container collects the concentrated sample liquid discharged from the discharge section. (2) The concentrating device according to (1) above, wherein the material of the porous membrane is at least one selected from the group consisting of cellulose acetate, polyethersulfone, hydrophilic polytetrafluoroethylene, glass fiber, nylon, polyvinylidene fluoride, and polyolefin. (3) The concentration device according to (1) or (2) above, wherein the porous membrane is made of a material having a surface energy of 24 dynes / cm or more and 75 dynes / cm or less. (4) The concentrating device according to any one of (1) to (3) above, wherein the swelling ratio of the superabsorbent polymer is greater than 0.2 g / g and less than 800 g / g. (5) The concentrating device according to any one of (1) to (4) above, wherein the highly water-absorbent polymer is a polyacrylic acid-based, polyacrylamide-based, cellulose-based, or polyethylene oxide-based polymer. (6) The concentrating device according to any one of (1) to (5) above, wherein the macromolecule contained in the biological fluid is an antigen. (7) The concentrating device according to any one of (1) to (6) above, wherein the sample liquid is urine. (8) The concentrating device according to (7) above, wherein the concentration of urea in the sample liquid concentrate is 5 times or less the concentration of urea in the sample liquid. (9) A method for concentrating a specimen liquid, comprising the steps of: concentrating a specimen liquid, which is an aqueous solution containing a macromolecule contained in a biological fluid, using the concentrating device according to any one of (1) to (8) above; a sample liquid injection step of injecting the sample liquid into the first container; a water absorption step in which a solution contained in the specimen liquid injected into the first container is absorbed by a highly water-absorbent polymer contained in the first container, thereby producing a specimen liquid concentrate in the first container, which is a concentrate of the specimen liquid; a discharging step of discharging the specimen liquid concentrate from the discharge portion by applying an external force to the specimen liquid concentrate; and a recovering step of recovering the concentrated specimen liquid discharged from the discharge section into the second container, in this order. (10) The method for concentrating a specimen liquid according to (9) above, wherein the external force is a centrifugal force. (11) The method for concentrating a specimen liquid according to (10) above, wherein the centrifugal force is applied under conditions of 4,000 to 10,000 revolutions per minute. (12) A method for testing a specimen liquid, comprising the steps of: detecting a polymer contained in the biological fluid in the specimen liquid, the polymer being an aqueous solution containing the polymer; a concentrating step of obtaining the above-mentioned sample liquid concentrate by using the method for concentrating the sample liquid according to any one of (9) to (11) above; a detection step of detecting a polymer contained in the biological fluid in the obtained concentrated specimen liquid, in this order. (13) The sample liquid is an aqueous solution that may contain an antigen, the concentrating step is a step of concentrating the aqueous solution that may contain the antigen using the method for concentrating a specimen liquid according to any one of (9) to (11) above to obtain an antigen concentrated liquid, The testing method according to (12) above, wherein the detection step is a step of detecting the antigen in the antigen concentrated solution by immunochromatography using an antigen-antibody reaction. (14) A test kit for detecting a polymer contained in a biological fluid in a sample solution which is an aqueous solution containing a polymer contained in the biological fluid, comprising: A concentrating device according to any one of (1) to (8) above, a detection device comprising: a test strip having a test area for detecting a polymer contained in the biological fluid, a first pot and a second pot containing a first amplification liquid and a second amplification liquid, respectively, for amplifying a test signal in the test area, and a housing case containing the test strip, the first pot, and the second pot; A test kit comprising: Effect of the Invention

[0008] As described below, the present invention can provide a concentrating device capable of concentrating a specimen liquid in a short period of time, a method for concentrating a specimen liquid using the concentrating device, a method for testing a specimen liquid using the method for concentrating a specimen liquid, and a test kit including the concentrating device and a detection device. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 is a schematic cross-sectional view of a preferred embodiment of a concentrating device of the present invention. [Diagram 2] FIG. 2 is a schematic cross-sectional view of a mini centrifugal filter used in the examples. [Figure 3A] FIG. 2 is a schematic cross-sectional view showing a sample liquid injection step in a preferred embodiment of the concentration method of the present invention in the order of steps. [Figure 3B] FIG. 2 is a schematic cross-sectional view showing a water absorption step in the process of a preferred embodiment of the concentration method of the present invention. [Figure 3C] FIG. 2 is a schematic cross-sectional view showing a discharge step in a preferred embodiment of the concentration method of the present invention in the order of steps. [Figure 3D] FIG. 2 is a schematic cross-sectional view showing a recovery process in a preferred embodiment of the concentration method of the present invention in the order of steps. [Figure 4] FIG. 2 is a schematic diagram of one embodiment of an insoluble carrier used in the detection step of the testing method of the present invention. [Diagram 5] FIG. 1 is a perspective view showing an aspect of one embodiment of an immunochromatography kit. [Figure 6] FIG. 1 is an exploded schematic perspective view showing an aspect of one embodiment of an immunochromatography kit. [Figure 7] FIG. 2 is a schematic side view showing the positional relationship between a test strip and a first and second pot. [Figure 8] 6 is a perspective view of a first convex deformation portion provided on an upper case of the immunochromatography kit shown in FIG. 5. FIG. [Figure 9] 9 is an end view of the cross section taken along line VV' in FIG. 8 before and after deformation of the first convex deformation portion. [Figure 10] 6 is a perspective view of a second convex deformation portion provided on the upper case of the immunochromatography kit shown in FIG. 5. [Figure 11] 11A and 11B are end views taken along line VII-VII' in FIG. 10 before and after deformation of the second convex deformation portion. [Figure 12] 13A to 13C are cross-sectional end views of a design modification example of a convexly deformed portion before and after deformation. [Figure 13] FIG. 1 is a perspective view of Amicon Ultra used in Comparative Examples A4 and B4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The concentrating device of the present invention, the method for concentrating a sample liquid of the present invention, the method for testing a sample liquid of the present invention, and the test kit of the present invention will be described below. In this specification, a numerical range expressed using "to" means a range that includes the numerical values ​​before and after "to" as the lower and upper limits. In the present specification, each component may be used alone or in combination of two or more. When two or more components are used in combination, the content of the components refers to the total content unless otherwise specified. In this specification, a shorter concentration time, an increased concentration rate, an increased detection sensitivity, and an increased S / N ratio (signal / noise ratio) are also simply referred to as the effects of the present invention being excellent.

[0011] [1] Concentration device The concentrating device of the present invention comprises: A concentrating device for concentrating a specimen liquid which is an aqueous solution containing a macromolecule contained in a biological fluid, comprising: The device includes a first container containing a highly absorbent polymer and a second container, The first container is partly constituted by a discharge part made of a porous membrane having a pore size of 0.05 μm or more and 10 μm or less, The superabsorbent polymer absorbs a solution (water, low molecular weight) contained in the sample liquid poured into the first container, and generates a sample liquid concentrate that is a concentrated solution of the sample liquid in the first container; The second container is a concentration device that collects the concentrated sample liquid discharged from the discharge section.

[0012] First, a preferred embodiment of the concentrating device of the present invention will be described with reference to the drawings. FIG. 1 is a schematic cross-sectional view of a preferred embodiment of a concentrating device of the present invention. As shown in FIG. 1, the concentration device 200 includes a first container 210 in which a superabsorbent polymer 230 is accommodated, and a second container 220. The bottom of the first container 210 is configured with a discharge part 212 made of a porous membrane having a pore size of 0.05 μm or more and 10 μm or less. The first container 210 has an opening 211. The second container 220 has an opening 221. The first container 210 is accommodated in the second container 220, and the first container 210 is fixed in the second container 220 so that a space is generated between the discharge part 212, which is the bottom of the first container 210, and the bottom surface of the second container.

[0013] Each of the components constituting the concentrating device of the present invention will be described below. The specimen liquid and the like will be explained in the method for concentrating a specimen liquid of the present invention described later.

[0014] [First container] As described above, a part of the first container is constituted by a discharge part made of a porous membrane having a pore size of 0.05 μm or more and 10 μm or less. Also, as described above, the first container contains a highly water-absorbent polymer.

[0015] The shape of the first container is not particularly limited, but is preferably cylindrical, and more preferably cylindrical.

[0016] The material of the first container is not particularly limited, but is preferably a thermoplastic resin because it can be injection molded and can be mass-produced at low cost.Specifically, polypropylene, acrylic, polyacetal, polyamide, polyethylene, polyethylene terephthalate, polycarbonate, polystyrene, polyphenylene sulfide, polybutylene terephthalate, polyvinyl chloride, ABS resin (acrylonitrile-butadiene-styrene copolymer resin), and AS resin (acrylonitrile-styrene copolymer resin) are preferred because they have a certain degree of hardness.

[0017] [Discharge section] As described above, a part of the first container is configured as a discharge part made of a porous membrane having a pore size of 0.05 μm or more and 10 μm or less. The position of the discharge part is not particularly limited, but it is preferable that the bottom of the first container is constituted by the above-mentioned discharge part.

[0018] <Porous membrane> The porous membrane constituting the discharge part has a pore size of 0.05 μm or more and 10 μm or less. Since the pore size of the porous membrane is 10 μm or less, when a specimen liquid is injected into the first container, the injected specimen liquid is retained in the first container without being discharged from the discharge part under atmospheric pressure.

[0019] (pore diameter) The upper limit of the pore size of the porous membrane is preferably 5 or less, more preferably 3 μm or less, and even more preferably 1 μm or less, for reasons such as better effects of the present invention. The lower limit of the pore size of the porous membrane is preferably 0.1 μm or more, more preferably 0.3 μm or more, and even more preferably 0.5 μm or more, for reasons such as better effects of the present invention. The pore size can be measured by known methods such as optical microscopy, mercury intrusion, and BET methods. In the present invention, the pore size is measured by the bubble point method (in accordance with JIS K 3832) using a perm porometer (manufactured by PMI).

[0020] (Material) The material of the porous membrane is not particularly limited, but from the viewpoint of the better effects of the present invention, it is preferably at least one selected from the group consisting of cellulose acetate (CA), polyethersulfone (PES), polytetrafluoroethylene (PTFE), glass fiber (GF), nylon, polyvinylidene fluoride (PVDF), and polyolefins, more preferably at least one selected from the group consisting of cellulose acetate (CA), polyethersulfone (PES), hydrophilic polytetrafluoroethylene (hydrophilic PTFE), glass fiber (GF), nylon, polyvinylidene fluoride (PVDF), and polyolefins, even more preferably at least one selected from the group consisting of cellulose acetate (CA), polyethersulfone (PES), glass fiber (GF), nylon, polyvinylidene fluoride (PVDF), and polyolefins, and particularly preferably at least one selected from the group consisting of cellulose acetate (CA), polyethersulfone (PES), and glass fiber (GF). In this specification, hydrophilic PTFE is PTFE having a surface energy of 25 dynes / cm or more, as described below, and hydrophobic PTFE is PTFE having a surface energy of less than 25 dynes / cm, as described below.

[0021] (Surface Energy) For reasons such as better effects of the present invention, the porous membrane is preferably made of a material having a surface energy of 24 dynes / cm or more and 75 dynes / cm or less, and more preferably made of a material having a surface energy of 40 dynes / cm or more and 75 dynes / cm or less. The above surface energy is measured by measuring the contact angle of droplets of water, diiodomethane (methylene iodide), and n-hexadecane dropped onto a polymer film in an environment of 20°C and 50% RH, and using the value calculated using the following method described in Reference 1. The surface energy is the dispersion component γ d , polar component γ p , hydrogen bonding component γ h Then, the surface energy is γ = γ d +γ p +γ h (...Equation (1)). The surface energy of the liquid is γ L , the surface energy of the solid is γ S The measured contact angle is θ, and the γ d , γ p , γ h The values ​​used are those given in Tables 1 to 3 in Reference 1, and the following formula (2) is used to calculate γ S d , γ S p , γ S h The surface energy is calculated by solving the following simultaneous equations: Gamma L (1+cosθ)=2(γ S d Gamma L d ) 1 / 2 +2(γ S p Gamma L p ) 1 / 2 +2(γ S h Gamma L h ) 1 / 2 (…Equation (2)) (Reference 1: Yasuaki Kitazaki et al., Journal of the Japan Adhesion Association, Vol. 8, No. 3, 1972, pp. 131-141)

[0022] [Superabsorbent polymer] The superabsorbent polymer (SAP) is not particularly limited, but is preferably a polyacrylic acid-based, polyacrylamide-based, cellulose-based, or polyethylene oxide-based polymer, because the effects of the present invention are more excellent.

[0023] <Swelling rate> The swelling ratio of the superabsorbent polymer is not particularly limited, but in order to obtain better effects of the present invention, it is preferably more than 0.2 g / g and less than 800 g / g, more preferably 1.0 g / g or more and 600 g / g or less, even more preferably 10 g / g or more and 500 g / g or less, and particularly preferably 20 g / g or more and 100 g / g or less. Here, the swelling ratio is a value defined as "the mass (g) of water held by 1 g of highly water-absorbent polymer."

[0024] (Method of measuring swelling ratio) The mass of the superabsorbent polymer stored at 25°C and 5% RH (relative humidity) for 10 days is measured, and then it is immediately immersed in a large amount of distilled water. After 120 minutes, the superabsorbent polymer is taken out, the water on the surface is removed, the mass is measured again, and the swelling ratio is calculated using the following formula. {(mass after water absorption (g) - initial mass before water absorption (g)) / initial mass before water absorption (g)}

[0025] The method for adjusting the swelling ratio to the above-mentioned specific range is not particularly limited, and examples of the method include changing the type of polymer, changing the molecular weight of the polymer, changing the degree of crosslinking, and changing the particle size.

[0026] <Water absorption rate> The water absorption rate of the superabsorbent polymer is not particularly limited, but for reasons such as better effects of the present invention, it is preferably 0.01 g / min or more and 40 g / min or less per 1 g of superabsorbent polymer, and more preferably 0.02 g / min or more and 40 g / min or less per 1 g of superabsorbent polymer.

[0027] The water absorption rate is measured as follows. The mass of the superabsorbent polymer stored at 25°C and 5% RH (relative humidity) for 10 days was measured (weight M 0 (unit: g), and then immediately immersed in a large amount of distilled water. After 10 minutes, the superabsorbent polymer is taken out, the water on the surface is removed, and the mass is measured (mass M 10 Immediately after the weight measurement, the polymer is immersed again in a large amount of distilled water. After 10 minutes, the superabsorbent polymer is taken out, the water on the surface is removed, and the weight is measured again (weight M 20 ). Mass M 20 Immediately after the measurement, the polymer is immersed in a large amount of distilled water again. After 10 minutes, the superabsorbent polymer is taken out, the water on the surface is removed, and the weight is measured again (mass M 30 ).

[0028] The water absorption is defined as follows: Water absorption in 10 minutes: ΔM10 = (M 10 -M 0 ) / M 0 Water absorption in 20 minutes: ΔM20 = (M 20 -M 0 ) / M 0 Water absorption in 30 minutes: ΔM30 = (M 30 -M 0 ) / M 0 Using the amount of absorbed water defined above, the rate of absorbed water is calculated as follows. Three points are plotted on an XY plane with time on the horizontal axis (x=10, 20, 30; unit: minutes) and water absorption on the vertical axis (y=ΔM10, ΔM20, ΔM30; unit: g water / g polymer amount). The slope of the linear approximation equation for the water absorption versus time using the least squares method is the water absorption rate per unit time (minute).

[0029] <Particle size> The superabsorbent polymer is preferably in the form of particles, and in this case, the particle size is preferably 10 mm or less, more preferably 8 mm or less, and even more preferably 5 mm or less, because the effects of the present invention are more excellent. The lower limit of the particle size of the superabsorbent polymer is preferably 0.001 mm or more, more preferably 0.005 mm or more, and even more preferably 0.01 mm or more, because the effects of the present invention are more excellent. The ratio of the particle size to the pore size of the porous membrane (particle size / pore size) is preferably 1 to 1000, and more preferably 10 to 100, for reasons such as better effects of the present invention. Here, the particle size can be determined as the arithmetic average value of diameters of 50 particulate polymer particles measured using an optical microscope.

[0030] [Second container] The second container is a container for collecting the concentrated specimen liquid discharged from the discharge portion of the first container. The second container preferably contains at least the discharge portion of the first container, and more preferably contains the entire first container. The preferred shapes and materials of the second container are the same as those of the first container.

[0031] [2] Method for concentrating sample liquid The method for concentrating a sample liquid of the present invention (hereinafter also referred to as the "concentration method of the present invention") comprises: A method for concentrating a specimen liquid, which is an aqueous solution containing a macromolecule contained in a biological fluid, using the concentrating device of the present invention described above, comprising the steps of: a sample liquid injection step of injecting the sample liquid into the first container; a water absorption step in which a solution (water, low molecular weight) contained in the specimen liquid injected into the first container is absorbed by a highly water-absorbent polymer contained in the first container, thereby producing a specimen liquid concentrate in the first container, which is a concentrate of the specimen liquid; a discharging step of discharging the specimen liquid concentrate from the discharge portion by applying an external force to the specimen liquid concentrate; and a recovery step of recovering the concentrated sample liquid discharged from the discharge section into the second container, in this order.

[0032] First, a preferred embodiment of the concentration method of the present invention will be described with reference to the drawings. FIG. 3 (FIG. 3A to FIG. 3D) are schematic cross-sectional views showing a preferred embodiment of the concentration method of the present invention in the order of steps.

[0033] First, in a specimen liquid injection step, specimen liquid 240 is injected into first container 210 from opening 221 of second container 220 and opening 211 of first container 210 of concentration device 200 of Fig. 1 described above (Fig. 3A). Concentration device 200 is as described above. Here, first container 210 has a bottom configured with outlet 212 made of a porous membrane with a pore size of 0.05 µm or more and 10 µm or less, and as described above, since the pore size of the porous membrane is 10 µm or less, the injected specimen liquid 240 is retained in first container 210 without being discharged from outlet 212.

[0034] Then, in the water absorption process, the solution (water, low molecular weight) contained in specimen liquid 240 is absorbed by superabsorbent polymer 230, and a concentrated specimen liquid 242, which is a concentrated liquid of specimen liquid 240, is produced in first container 210 (superabsorbent polymer 230 becomes swollen superabsorbent polymer 232) (Figure 3B).

[0035] Next, in the discharge step, the concentrating device 202 after the water absorption step is placed in a small tabletop centrifuge, and centrifugal force is applied to the specimen liquid concentrate 242 in the top-to-bottom direction (toward the discharge part) in FIG. 3C, so that the specimen liquid concentrate 242 is discharged from the discharge part 212 (FIG. 3C). As described above, since the pore size of the porous membrane is 0.05 μm or more, it is possible to discharge the specimen liquid concentrate 242 even with a small tabletop centrifuge (for example, 4,000 to 10,000 revolutions per minute (rpm)) (in the case of an ultrafiltration device such as that described in Patent Document 1, a large centrifuge is required). In addition, only one centrifugation is required (in the case of an ultrafiltration device such as that described in Patent Document 1, two centrifugations are required as shown in Comparative Examples A4 and B4 described later). Thus, compared to the ultrafiltration device such as that described in Patent Document 1, the above method is extremely simple (a small tabletop centrifuge can be used, and only one centrifugation is required).

[0036] Then, in the recovery step, concentrated specimen liquid 242 discharged from discharge portion 212 is recovered in second container 220 (FIG. 3D). In this manner, concentrated specimen liquid can be obtained.

[0037] Each step will be described below.

[0038] [Sample liquid injection process] The specimen liquid injection step is a step of injecting the specimen liquid into the first container of the concentrating device of the present invention described above. The specimen liquid is injected into the first container by the specimen liquid injection step, and the specimen liquid is mixed with the superabsorbent polymer contained in the first container. Here, the first container is partly constituted by an outlet part made of a porous membrane having a pore size of 0.05 μm or more and 10 μm or less, and as described above, since the pore size of the porous membrane is 10 μm or less, the injected specimen liquid is retained in the first container without being discharged from the outlet part.

[0039] [Concentration device] The concentrating device of the present invention is described above.

[0040] [Sample liquid] The specimen liquid is an aqueous solution containing macromolecules contained in biological fluids. Specific examples of the above-mentioned sample fluid include animal (particularly human) body fluids (eg, blood, serum, plasma, cerebrospinal fluid, tears, sweat, urine, pus, nasal discharge, or sputum), gargling fluid, and the like. The above-mentioned sample liquid is preferably urine because the effects of the present invention are more excellent.

[0041] <Polymers contained in biological fluids> Examples of the polymers (particularly antigens) contained in the biological fluids are polymers that are useful mainly for determining disease, and include bacteria, germs (e.g., Mycobacterium tuberculosis, lipoarabinomannan (LAM) contained in Mycobacterium tuberculosis), bacteria, viruses (e.g., influenza virus), and their nucleoproteins, which are detected in biological fluids. LAM is a major antigen in tuberculosis, and is a glycolipid that is a major component of cell membranes and cell walls. The polymer contained in the biological fluid is preferably an antigen, more preferably a virus (in particular, influenza virus) or LAM, and even more preferably LAM, for reasons that result in better effects of the present invention.

[0042] The concentration of the polymer contained in the biological fluid in the sample liquid is not particularly limited, but in order to obtain better effects of the present invention, it is preferably 0.0001 ng / mL or more and 1 mg / mL or less, more preferably 0.001 ng / mL or more and 1 μg / mL or less, and even more preferably 0.01 ng / mL or more and 1 ng / mL or less.

[0043] <Pretreatment of sample liquid> The above-mentioned sample liquid can be used as it is, or in the form of an extract obtained by extracting the antigen using an appropriate extraction solvent, or further in the form of a diluted solution obtained by diluting the extract liquid with an appropriate diluent, or in the form of the extract liquid concentrated by an appropriate method. As the extraction solvent, a solvent used in a conventional immunological analysis method (e.g., water, physiological saline, buffer solution, etc.) or a water-miscible organic solvent that can directly carry out an antigen-antibody reaction by diluting with such a solvent can be used.

[0044] [Ratio of superabsorbent polymer to sample liquid] The ratio of the superabsorbent polymer to the sample liquid is not particularly limited, but for reasons such as better effects of the present invention, it is preferably 0.01 to 100 g, and more preferably 0.1 to 50 g, per 1 mL of sample liquid.

[0045] [Water absorption process] The water absorption process is a process in which the solution (water, low molecular weight) contained in the specimen liquid injected into the first container is absorbed by the highly absorbent polymer contained in the first container, producing a specimen liquid concentrate, which is a concentrated solution of the specimen liquid, in the first container. When a specimen liquid is mixed with a superabsorbent polymer, the solution (water, low molecular weight) in the specimen liquid is taken up by the superabsorbent polymer, whereas the macromolecules (e.g., antigens) contained in the biological fluid in the specimen liquid have a certain degree of hydrodynamic radius, and therefore the mesh structure on the surface of the superabsorbent polymer creates a sieving effect, making it difficult for them to be taken up by the superabsorbent polymer. As a result, the macromolecules (e.g., antigens) contained in the biological fluid in the specimen liquid are concentrated.

[0046] When the above-mentioned sample liquid is urine, the concentration of urea in the concentrated sample liquid is preferably 5 times or less the concentration of urea in the sample liquid, for reasons such as better effects of the present invention.

[0047] The water absorption step may be, for example, a method of leaving the device of the present invention after the above-mentioned sample liquid injection step, etc. Although the time for leaving the device is not particularly limited, it is preferably 1 to 30 minutes, and more preferably 1 to 10 minutes, because the effects of the present invention are more excellent.

[0048] [Discharge process] The discharge step is a step of discharging the specimen liquid concentrate from the discharge portion by applying an external force to the specimen liquid concentrate. By applying an external force to the specimen liquid concentrate, the specimen liquid concentrate is pressed against the discharge portion, and the specimen liquid concentrate is discharged from the discharge portion. The external force is preferably a centrifugal force because this provides better effects of the present invention. The centrifugal force is preferably applied using a small (eg, 50 cm cubic or less) tabletop centrifuge (small tabletop centrifuge) because this provides better effects of the present invention. The centrifugal force is preferably applied under conditions (rotation speed) of 4,000 to 10,000 revolutions / minute, because this provides better effects and the like of the present invention.

[0049] [Recovery process] The recovery step is a step of recovering the concentrated specimen liquid discharged from the discharge part into a second container. In this manner, a concentrated sample liquid can be obtained.

[0050] [3] Testing method for sample fluid The method for testing a sample liquid of the present invention (hereinafter also referred to as the "test method of the present invention") comprises: A method for testing a specimen liquid, comprising the steps of: detecting a polymer contained in the specimen liquid, the polymer being an aqueous solution containing the polymer; a concentrating step of obtaining the above-mentioned sample liquid concentrate by using the above-mentioned method for concentrating a sample liquid of the present invention (the above-mentioned concentrating method of the present invention); and a detection step of detecting a polymer contained in the biological fluid in the obtained concentrated specimen liquid.

[0051] In the testing method of the present invention, a high detection sensitivity can be achieved since the concentrated specimen liquid obtained by the above-mentioned concentration method of the present invention is used to detect macromolecules contained in a biological fluid.

[0052] [Concentration process] The method for obtaining a sample liquid concentrate using the concentration method of the present invention is as described above.

[0053] [Detection process] The detection step is a step of detecting a polymer contained in the biological fluid in the concentrated specimen liquid. The detection step is preferably a method using an antigen-antibody reaction because it provides better effects of the present invention, and examples of such methods include enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescent immunoassay (FIA), Western blotting, immunochromatography, etc. Among these, immunochromatography is preferred because it provides better effects of the present invention.

[0054] [Preferred embodiment] The inspection method of the present invention has the following advantages, because the effects of the present invention are superior: The sample liquid is an aqueous solution that may contain an antigen (a macromolecule contained in a biological fluid), The concentrating step is a step of concentrating the aqueous solution that may contain the antigen using the concentrating method of the present invention described above to obtain an antigen concentrate (sample liquid concentrate), The detection step is preferably a testing method in which the antigen in the concentrated antigen solution is detected by immunochromatography using an antigen-antibody reaction.

[0055] Here, the detection step is performed in such a manner that the effects of the present invention are more excellent. a spreading step of forming a gold particle complex, which is a complex between the antigen in the antigen concentrated solution and a modified gold particle, which is a gold particle modified with a first binding substance capable of binding to the antigen, on an insoluble carrier having a reaction site at which a second binding substance capable of binding to the antigen is immobilized; It is preferable to further include a capture step of capturing the gold particle complex at the reaction site of the insoluble carrier. The above detection step is carried out because the effects of the present invention are more excellent. Furthermore, it is preferable to have a silver amplification step in which the gold particle complex captured in the above-mentioned capture step is subjected to silver amplification. Here, for reasons such as better effects of the present invention, it is preferable that at least one of the first binding substance and the second binding substance is a monoclonal antibody, and it is more preferable that both the first binding substance and the second binding substance are monoclonal antibodies.

[0056] The specimen liquid may contain impurities such as low molecular weight components and salts. For example, when the specimen liquid is urine, impurities such as urea are contained. The inventors' studies have revealed that when these impurities are concentrated together with the macromolecules contained in the biological fluid, the antigen-antibody reaction may be inhibited, resulting in a decrease in detection sensitivity. In other words, it has been found that the effect of improving detection sensitivity by concentration may not be sufficiently obtained. Therefore, in the concentrating device of the present invention used in the concentrating step, the swelling ratio of the superabsorbent polymer is preferably within the above-mentioned preferred range. When the swelling ratio is within the above-mentioned range, these impurities are taken up into the superabsorbent polymer together with water, and the above-mentioned decrease in detection sensitivity is unlikely to occur, and as a result, it is believed that an extremely high detection sensitivity is achieved.

[0057] Each step of the above-mentioned preferred embodiment (hereinafter also referred to as "the method of the present invention") will be described below.

[0058] [Development process] The spreading step is a step of spreading a gold particle complex, which is a complex between the antigen in the antigen concentrate obtained in the concentration step described above and modified gold particles, which are gold particles modified with a first binding substance capable of binding to the antigen, onto an insoluble carrier having a reaction site at which a second binding substance capable of binding to the antigen is immobilized.

[0059] <Gold particle composite> As described above, in the development process, first, a gold particle complex is formed, which is a complex between the antigen in the antigen concentrate obtained in the concentration process described above and modified gold particles, which are gold particles modified with a first binding substance capable of binding to the antigen.

[0060] (modified gold particles) The modified gold particles are gold particles modified with a first binding substance capable of binding to the above-mentioned antigen.

[0061] (1) Gold particles The gold particles are not particularly limited, but gold colloid particles are preferred because they provide better effects of the present invention. When the method of the present invention includes a silver amplification step described below, the gold particles act as a catalyst for reducing silver ions in the silver amplification step.

[0062] For reasons such as better effects of the present invention, the particle size of the gold particles is preferably 500 nm or less, more preferably 300 nm or less, even more preferably 200 nm or less, and particularly preferably 100 nm or less. There is no particular lower limit to the particle size of the gold particles, but for reasons such as better effects of the present invention, the particle size is preferably 1 nm or more, more preferably 2 nm or more, and even more preferably 5 nm or more.

[0063] The particle size can be measured by a commercially available particle size distribution meter. Methods for measuring particle size distribution include optical microscopy, confocal laser microscopy, electron microscopy, atomic force microscopy, static light scattering, laser diffraction, dynamic light scattering, centrifugal sedimentation, electric pulse measurement, chromatography, and ultrasonic attenuation, and devices corresponding to each principle are commercially available. As a method for measuring particle size, dynamic light scattering can be preferably used because of the particle size range and ease of measurement. Commercially available measuring devices using dynamic light scattering include Nanotrack UPA (Nikkiso Co., Ltd.), dynamic light scattering particle size distribution measuring device LB-550 (Horiba Ltd.), and concentrated particle size analyzer FPAR-1000 (Otsuka Electronics Co., Ltd.), and in the present invention, the median diameter (d=50) measured at a measurement temperature of 25°C is obtained.

[0064] (2) First binding substance The first binding substance is not particularly limited as long as it is capable of binding to the above-mentioned antigen, but in order to obtain better effects of the present invention, it is preferably a protein, more preferably an antibody (e.g., a polyclonal antibody or a monoclonal antibody), and even more preferably a monoclonal antibody in terms of achieving higher detection sensitivity. The above-mentioned antibody is not particularly limited, and for example, antiserum prepared from the serum of an animal immunized with an antigen, or an immunoglobulin fraction purified from the antiserum can be used, and a monoclonal antibody obtained by cell fusion using spleen cells of an animal immunized with an antigen, or a fragment thereof [e.g., F(ab')2, Fab, Fab', or Fv] can be used. These antibodies can be prepared by conventional methods.

[0065] When the antigen is LAM, an example of the first binding substance is the A194-01 antibody described in WO 2017 / 139153. The contents of WO 2017 / 139153 regarding the A194-01 antibody are all incorporated herein by reference as part of the disclosure of the present specification. Another example of the first binding substance when the antigen is LAM is an antibody having a sequence described as MoAb1 in paragraph

[0080] of WO 2013 / 129634. The entire contents of WO 2013 / 129634 regarding the MoAb1 antibody are incorporated herein by reference as part of the disclosure of the present specification.

[0066] (3) Method for producing modified gold particles The method for producing the modified gold particles is not particularly limited, and known methods can be used. For example, a chemical bonding method utilizing the chemical bonding between gold and SH groups includes introducing SH groups into an antibody, and then immobilizing the antibody via Au-S bonds that are generated on the Au surface when the antibody approaches the gold particles and the SH bonds are cleaved.

[0067] <Insoluble carrier> The insoluble carrier has a reaction site (test line) where a second binding substance capable of binding to the antigen is immobilized. The insoluble carrier may have a plurality of test lines according to the types of antigens (for example, a test line for influenza A virus and a test line for influenza B virus). The insoluble carrier may also have a control line downstream of the test line in order to confirm the development of the gold particle complex. In addition, when a reducing agent solution is used in the silver amplification step described later, the insoluble carrier may have a color-developing reagent immobilized line downstream of the test line in order to detect the reducing agent solution. A specific embodiment of the insoluble carrier is, for example, a nitrocellulose membrane 300 having, from the upstream side, a gold colloid holding pad 301, a test line 302, a control line 303, and a color-developing reagent immobilized line 304, as shown in Fig. 4. Here, the gold colloid holding pad 301 is a pad that holds gold particles modified with a first binding substance (modified gold particles), the test line 302 is a line to which a second binding substance is immobilized, the control line 303 is a line for confirming development, and the color-developing reagent immobilized line 304 is a line for detecting a reducing agent solution, which will be described later. Here, the terms "upstream side" and "downstream side" refer to the development of the gold particle complex from the upstream side to the downstream side when the gold particle complex develops. More specific examples of the above-mentioned insoluble carrier (or an immunochromatographic kit having the same) include the insoluble carrier and immunochromatographic kit described in Japanese Patent No. 5728453, and all of the contents of Japanese Patent No. 5728453 relating to the insoluble carrier and the immunochromatographic kit are incorporated herein by reference as part of the disclosure of this specification.

[0068] (Insoluble Carrier) The insoluble carrier is preferably a porous carrier. In particular, because the effects of the present invention are more excellent, a nitrocellulose membrane, a cellulose membrane, an acetylcellulose membrane, a polysulfone membrane, a polyethersulfone membrane, a nylon membrane, a glass fiber, a nonwoven fabric, a cloth, or a thread is preferred, and a nitrocellulose membrane is more preferred.

[0069] (Second binding substance) The second binding substance is not particularly limited as long as it is capable of binding to the above-mentioned antigen. Specific examples and preferred aspects of the second binding substance are the same as those of the first binding substance described above.

[0070] The second binding substance may be the same as or different from the first binding substance described above, but in order to obtain better effects of the present invention, it is preferable that the second binding substance is a different substance. Furthermore, when the first binding substance and the second binding substance are antibodies, it is preferable that the antibody as the first binding substance and the antibody as the second binding substance are different in order to obtain better effects of the present invention. Furthermore, when the first binding substance and the second binding substance are antibodies, it is preferable that the epitope of the first binding substance (a part of the antigen recognized by the first binding substance) and the epitope of the second binding substance (a part of the antigen recognized by the second binding substance) are different, because this provides better effects of the present invention, etc. The fact that the epitopes of the antibodies are different can be confirmed, for example, by ELISA (Enzyme-Linked Immunosorbent Assay).

[0071] <Expand> There is no particular limitation on the method for spreading the gold particle complex formed on an insoluble carrier having a test line, but an example of such a method includes preparing a nitrocellulose membrane 300 (or an immunochromatography kit having the same) as shown in Figure 4 described above, dripping the antigen concentrate obtained in the concentration process described above onto a gold colloid retention pad, and using capillary action to move the antigen from the upstream side to the downstream side as shown in Figure 4.

[0072] [Capturing process] The capture step is a step of capturing the gold particle complex at the reaction site of the insoluble carrier. As described above, a second binding substance capable of binding to an antigen is immobilized at the reaction site of the insoluble carrier, so that the gold particle complex (complex of antigen and modified gold particle) developed on the insoluble carrier in the development step is captured at the reaction site (test line) of the insoluble carrier. The captured gold particle complex is colored by the surface plasmon of the gold particle, and can be visually recognized. In addition, the concentration of the captured complex can be estimated using an image analyzer, etc. In this way, the antigen in the sample can be detected. If the sample does not contain the antigen, the gold particle complex is not formed, so that the antigen is not captured at the reactive site on the insoluble carrier and is not colored.

[0073] [Silver Amplification Process] The silver amplification step is a step of silver-amplifying the gold particle complex captured in the above-mentioned capture step. The silver amplification step is a step of forming large silver particles in the gold particle complex captured at the reaction site of the insoluble carrier by adding silver ions to the insoluble carrier after the capture step. More specifically, it is a step of forming silver particles (e.g., 10 μm or more in diameter) by reducing the silver ions using the gold particles of the gold particle complex as a catalyst. This significantly improves the detection sensitivity of the captured gold particle complex. The silver amplification step may be carried out together with the development step, or the silver amplification step may serve as the development step.

[0074] <Preferred embodiment> The method for providing silver ions to the insoluble carrier after the above capture step is not particularly limited, but a method using the following reducing agent solution and the following silver amplification solution is preferred because it provides better effects of the present invention. In addition to the reducing agent solution and the silver amplification solution, a washing solution may be used to wash away the complex remaining on the insoluble carrier other than that resulting from the specific binding reaction. The reducing solution may also serve as the washing solution.

[0075] (Reducing agent liquid) The reducing agent solution contains a reducing agent capable of reducing silver ions. The reducing agent capable of reducing silver ions can be any inorganic or organic material or a mixture thereof, as long as it can reduce silver ions to silver. As an inorganic reducing agent, Fe 2+ , V 2+ , Ti 3+ Preferred examples of reducing metal salts and reducing metal complex salts are those in which the valence can be changed by metal ions such as Fe. When using an inorganic reducing agent, it is necessary to form a complex or reduce the oxidized ions, and remove or render them harmless. For example, Fe 2+ In the system using ethylenediaminetetraacetic acid (EDTA) as a reducing agent, the oxide Fe 3+ In the present invention, it is preferable to use such an inorganic reducing agent. In a more preferable embodiment of the present invention, Fe 2+ It is preferable to use a metal salt of the above as the reducing agent.

[0076] In addition, developing agents used in wet silver halide photographic light-sensitive materials (e.g., methyl gallate, hydroquinone, substituted hydroquinone, 3-pyrazolidones, p-aminophenols, p-phenylenediamines, hindered phenols, amidoximes, azines, catechols, pyrogallols, ascorbic acid (or its derivatives), and leuco dyes), as well as other materials obvious to those skilled in the art, such as those described in U.S. Pat. No. 6,020,117, can also be used as reducing agents.

[0077] The reducing agent is preferably an ascorbic acid reducing agent. Useful ascorbic acid reducing agents include ascorbic acid and its analogs, isomers and its derivatives, and examples of the reducing agents include D- or L-ascorbic acid and its sugar derivatives (e.g., γ-lactoascorbic acid, glucoascorbic acid, fucoascorbic acid, glucoheptoascorbic acid, maltoascorbic acid), sodium salt of ascorbic acid, potassium salt of ascorbic acid, isoascorbic acid (or L-erythroascorbic acid), salts thereof (e.g., alkali metal salts, ammonium salts or salts known in the art), enediol type ascorbic acid, enaminol type ascorbic acid, thioenol type ascorbic acid, etc., and particularly D, L or D,L-ascorbic acid (and its alkali metal salts) or isoascorbic acid (or its alkali metal salts), with sodium salts being the preferred salts. If necessary, a mixture of these reducing agents can be used.

[0078] For reasons such as better effects of the present invention, the reducing agent liquid is preferably flowed so that the angle between the development direction in the development process and the development direction of the reducing agent liquid is 0 degrees to 150 degrees, and more preferably flowed so that the angle between the development direction in the development process and the development direction of the reducing agent liquid is 0 degrees to 135 degrees. As a method for adjusting the angle between the developing direction in the developing step and the developing direction of the reducing agent solution, for example, there may be mentioned a method described in the examples of JP-A-2009-150869.

[0079] (Silver amplification solution) The silver amplification liquid is a liquid containing a compound containing silver ions. Examples of the compound containing silver ions include organic silver salts, inorganic silver salts, and silver complexes. Preferred examples of the silver ion-containing compound include silver nitrate, silver acetate, silver lactate, silver butyrate, and silver thiosulfate, which are highly soluble in solvents such as water. Silver nitrate is particularly preferred. Preferred examples of the silver complex include silver complexes coordinated with a ligand having a water-soluble group such as a hydroxyl group or a sulfonic group, and examples of the silver complex include hydroxythioether silver.

[0080] The organic silver salt, inorganic silver salt, or silver complex is contained in the silver amplification solution at a concentration of 0.001 mol / L to 5 mol / L, preferably 0.005 mol / L to 3 mol / L, and more preferably 0.01 mol / L to 1 mol / L, in terms of silver.

[0081] Examples of auxiliary agents for the silver amplification solution include buffers, preservatives, such as antioxidants or organic stabilizers, and speed regulators. Examples of buffers that can be used include buffers using acetic acid, citric acid, sodium hydroxide or one of their salts, or tris(hydroxymethyl)aminomethane, and other buffers used in general chemical experiments. By using these buffers appropriately, the amplification solution can be adjusted to an optimal pH. As an antifogging agent, an alkylamine can be used as an auxiliary agent, and dodecylamine is particularly preferred. To improve the solubility of these auxiliary agents, a surfactant can be used, and C is particularly preferred. 9 H 19 -C 6 H 4 -O-(CH 2 CH 2 O) 50 It's H.

[0082] For reasons such as better effects of the present invention, it is preferable to flow the silver amplification liquid in the opposite direction to the development step described above, and it is more preferable to flow the silver amplification liquid so that the angle between the development direction in the development step and the development direction of the reducing agent liquid is 45 degrees to 180 degrees. As a method for adjusting the angle between the developing direction in the developing step and the developing direction of the silver amplification solution, for example, there can be mentioned the method described in the examples of JP-A-2009-150869.

[0083] [4] Test kits The test kit of the present invention comprises: A test kit for detecting a polymer contained in a biological fluid in a sample solution which is an aqueous solution containing a polymer contained in the biological fluid, comprising: The concentrating device of the present invention as described above, a detection device comprising: a test strip having a test area for detecting a polymer contained in the biological fluid, a first pot and a second pot containing a first amplification liquid and a second amplification liquid, respectively, for amplifying a test signal in the test area, and a housing case containing the test strip, the first pot, and the second pot; The test kit comprises:

[0084] [Concentration device] The concentrating device of the present invention is described above.

[0085] [Detection Device] The detection device is The detection device comprises a test strip having a test area for detecting polymers contained in the biological fluid, a first pot and a second pot containing a first amplification liquid and a second amplification liquid, respectively, for amplifying a test signal in the test area, and a housing case containing the test strip, the first pot, and the second pot.

[0086] [Preferred embodiment] Preferred embodiments of the above-mentioned detection device will now be described.

[0087] The above detection device has the following advantages: An immunochromatography kit for detecting a test substance (polymer contained in a biological fluid) in a sample liquid (analyte liquid), comprising: A test strip including an insoluble carrier having a test area for a test substance on which a sample liquid is developed; a first pot and a second pot each having one surface provided with a sheet member and each filled with a first amplification liquid and a second amplification liquid for amplifying a detection signal in a test region; a housing case containing a test strip, a first pot and a second pot; the housing case includes a lower case having a storage portion in which a test strip is placed, an upper case joined to the lower case at a periphery, and an intermediate member disposed between the upper case and the lower case; The intermediate member has a breaking portion that breaks the sheet member of the first pot and faces the sheet member of the first pot; It is preferable that the upper case is an immunochromatography kit (hereinafter also referred to as the "immunochromatography kit of the present invention" or simply "immunochromatography kit") which comprises a first convex deformation portion which deforms toward the first pot when external pressure is applied to the portion facing the first pot, and breaks the sheet member of the first pot at the breaking portion of the intermediate member, and a second convex deformation portion which deforms toward the second pot when external pressure is applied to the portion facing the second pot, and breaks the sheet member of the second pot.

[0088] In the immunochromatography kit of the present invention, it is preferable that the first convex deformation portion, when a pressing force is applied, moves the first pot to a position where the sheet member is broken by the breaking portion of the intermediate member. In this case, it is preferable that the upper case has two protrusions extending upright toward the first pot, which come into contact with and move the first pot when a pressing force is applied to the first convex deformation portion.

[0089] In the immunochromatography kit of the present invention, it is preferable that the first convex deformation portion has a centrally symmetric mountain shape. In this case, it is preferable that the two protrusions are disposed symmetrically with respect to the apex of the mountain shape. It is also preferable that the two protrusions are formed independently of each other on the slopes that sandwich the apex of the mountain shape.

[0090] In the immunochromatography kit of the present invention, when the first convex deformation portion has the two protrusions described above, it is preferable that the two protrusions are arranged symmetrically with respect to the center of the abutment surface of the first pot. In addition, it is preferable that the two protrusions are disposed closer to the end than half the distance from the center of the contact surface of the first pot to the end.

[0091] In this specification, a convexly deformed portion means that it is convex when viewed from the outside of the immunochromatography kit, and similarly, a mountain-shaped portion means that it is mountain-shaped when viewed from the outside.

[0092] In the immunochromatography kit of the present invention, when the first convex deformation portion is provided with the two protrusions described above, the tips of each of these two protrusions can be configured to abut against the first pot and gradually displace toward the end, thereby moving the first pot.

[0093] In the immunochromatography kit of the present invention, the material constituting the first convex deformation portion preferably has a flexural modulus of elasticity of 50 MPa to 350 MPa. It is also preferable that the material constituting the upper case has a flexural modulus of 50 MPa to 350 MPa, and that the material constituting the lower case has a flexural modulus of 500 MPa to 900 MPa.

[0094] In the immunochromatography kit of the present invention, it is preferable that the upper case is formed integrally with the first convex deformation portion and the second convex deformation portion by injection molding.

[0095] The immunochromatography kit of the present invention has a first convex deformation part that deforms to the first pot side by applying a pressing force from the outside to a part facing the first pot, and breaks the sheet member of the first pot by the breaking part of the intermediate member, and a second convex deformation part that deforms to the second pot side by applying a pressing force from the outside to a part facing the second pot, and breaks the sheet member of the second pot. By applying a pressing force with a finger or the like to the two convex deformation parts, the sheet member of the pot can be deformed and broken, and the amplification liquid can be supplied to the test strip, so that the amplification reaction can be normally performed even without a dedicated analysis device that requires a power source. Therefore, the immunochromatography kit of the present invention is particularly useful in emergencies, disasters, etc. where a dedicated analysis device is not provided or an analysis device cannot be used.

[0096] Hereinafter, an embodiment of the immunochromatography kit of the present invention will be described with reference to the drawings, but the immunochromatography kit of the present invention is not limited to this. Note that, for ease of visualization, the scale of each component in the drawings has been appropriately changed from the actual one.

[0097] FIG. 5 is a schematic perspective view of an immunochromatography kit 100 according to an embodiment of the present invention, and FIG. 6 is a schematic exploded perspective view of the immunochromatography kit 100 of FIG. As shown in Fig. 5 and Fig. 6, the immunochromatography kit 100 of this embodiment includes a test strip 1 including an insoluble carrier 2 having a test region for a test substance for developing a sample liquid, and a first pot 40 and a second pot 45 each having a surface with a sheet member and containing a first amplifying liquid 41 and a second amplifying liquid 46, respectively, for amplifying a detection signal in the test region, which are enclosed in a housing case 9. The housing case 9 includes a lower case 20 having a storage section 21 in which the test strip 1 is placed, an upper case 10 joined to the lower case 20 at its periphery, and an intermediate member 30 disposed between the upper case 10 and the lower case 20. In describing the immunochromatography kit 100, the upper case 10 side is defined as the top, and the lower case 20 side is defined as the bottom.

[0098] Intermediate member 30 has pot accommodating section 32 which receives first pot 40 and has an amplification liquid filling hole on its bottom surface for dropping first amplification liquid 41 onto insoluble carrier 2. Also, protruding breaking portion 34 for breaking sheet member 43 is provided at a position facing sheet member 43 of first pot 40 in pot accommodating section 32. In this example, first pot 40 is disposed above pot accommodating section 32 such that the surface having sheet member 43 faces downward, and breaking portion 34 is provided on the bottom surface of pot accommodating section 32 which faces sheet member 43 (see FIG. 7). The intermediate member 30 also includes a flow path forming portion 35 extending downstream of the bottom surface of the pot receiving portion 32. The flow path forming portion 35 is disposed in the testing region L 1 , confirmation area L 2 and amplification indicator region L 3 These regions L 1 ~L 3 It is made of a transparent material so that the

[0099] The upper case 10 has a first convex deformation portion 12 that deforms toward the first pot 40 when a pressing force is applied from the outside, and breaks the sheet member 43 of the first pot 40 at the breaking portion 34 of the intermediate member 30. The upper case 10 also has a second convex deformation portion 14 that deforms toward the second pot 45 when a pressing force is applied from the outside, and breaks the sheet member 48 of the second pot 45. The upper case 10 is also provided with an opening 16 for dropping sample liquid, and the sample liquid is dropped onto the marker-retaining pad 3 of the test strip 1 through this opening 16. By adjusting the position of the marker-retaining pad 3 so that the opening 16 and the position of the marker-retaining pad 3 coincide with each other, it is possible to reliably drop the sample liquid onto the marker-retaining pad 3. The upper case 10 is also provided with three regions L 1 ~L 3 An observation window 18 is provided for visually observing the

[0100] The lower case 20 is provided with an insoluble carrier housing section 21 on which the insoluble carrier 2 is placed, and an absorbent pad housing section 22 on which the absorbent pad 6 is placed, downstream of the insoluble carrier housing section 21, as housing sections in which the test strip 1 is placed. Also, a second pot housing section 24 in which a second pot 45 is placed is provided upstream of the insoluble carrier housing section 21.

[0101] FIG. 7 is a schematic cross-sectional view showing the positional relationship between the test strip 1, the intermediate member 30, and the two pots 40, 45. As shown in FIG. 7, the test strip 1 includes an insoluble carrier 2 for developing the sample liquid, a label retaining pad 3 containing a labeling substance modified with a first substance capable of binding to the test substance fixed on the insoluble carrier 2, a liquid delivery pad 4 for delivering a second amplification liquid 46 to the insoluble carrier 2, which is arranged in contact with one end of the insoluble carrier 2, and an absorbent pad 6 arranged in contact with the other end of the insoluble carrier 2. The insoluble carrier 2 is fixed and supported on a back adhesive sheet 7. The insoluble carrier 2 has a test region L containing a second substance that binds to the test substance between the label retaining pad 3 and the absorbent pad 6.1 , a confirmation region L containing a substance capable of binding to a first substance 2 , an amplification indicator region L containing a substance that reacts with the second amplification solution 3 are provided in this order from the label holding pad 3 side.

[0102] In this specification, the inspection area L 1 , confirmation area L 2 and amplification indicator region L 3 The insoluble carrier 2 on which the above is formed is sometimes referred to as a chromatographic carrier. In addition, in this specification, the liquid delivery pad 4 side is defined as the upstream side, and the absorbent pad 6 side is defined as the downstream side, as shown in FIG.

[0103] The intermediate member 30 is located above the downstream end side of the test strip 1, and the first pot 40 is disposed in the pot accommodating portion 32 of the intermediate member 30 with the sheet member 43 facing downward. The second pot 45 is accommodated below the upstream end of the test strip 1 in the lower case 20 with the sheet member 48 facing upward.

[0104] 7, a gap (clearance) D is formed between the back surface 36 of the flow path forming portion 35 of the intermediate member 30 and the insoluble carrier 2 of the test strip 1. This gap D is preferably in the range of 0.01 mm to 1 mm. If it is 0.01 mm or more, the amplification liquid and the like can be sufficiently infiltrated, and if it is 1 mm or less, capillary force is exerted, and it is possible for the first amplification liquid 41 to uniformly fill the gap between the insoluble carrier 2 and the intermediate member 30.

[0105] The first pot 40 containing the first amplification liquid 41 is filled in a container 42 having an opening on one side and made of, for example, a resin material, and the opening of the container 42 is covered and sealed by a breakable sheet member 43. Similarly, the second pot 45 containing the second amplification liquid 46 is filled in a container 47 having an opening on one side and made of, for example, a resin material, and the opening of the container 47 is covered and sealed by a breakable sheet member 48. A laminate film such as an aluminum foil or an aluminum laminate sheet is preferably used as the breakable sheet members 43, 48 in the first pot 40 and the second pot 45. Breaking here refers to a state in which the material cannot be restored after being broken.

[0106] The two convex deformation portions 12 and 14 of the upper case will now be described in detail. Figure 8 is an oblique view showing the first convex deformation portion 12, and Figure 9 is a cross-sectional end view taken along line V-V' in Figure 8, where A in Figure 9 shows the first convex deformation portion 12 before deformation and B in Figure 9 shows the first convex deformation portion 12 after deformation, showing its positional relationship with the first pot 40.

[0107] The first convex deformation portion 12, when pressed, moves the first pot 40 to a position where the sheet member 43 is broken by the breaking portion 34 of the intermediate member 30. Specifically, the first convex deformation portion 12 is configured so that it can be pushed downward by being pressed down with a finger or the like, and by deforming the first convex deformation portion 12 so as to be convex downward (to be concave when viewed from the outside), the first pot 40 is moved toward the breaking portion 34 to a position where the sheet member 43 of the first pot 40 is broken by the breaking portion 34 in the pot storage portion 32 of the intermediate member 30. This allows the breaking portion 34 to break the sheet member 43 of the first pot 40, and the first amplification liquid 41 can be supplied to the outside. The first amplification liquid 41 is dripped onto the upper part of the insoluble carrier 2 from an amplification liquid filling hole provided on the bottom surface of the pot storage portion 32 of the intermediate member 30, and the first amplification liquid 41 is dripped onto the test area L on the insoluble carrier. 1 , confirmation area L 2 and amplification indicator region L 3 At this time, the first amplification liquid 41 dropped onto the insoluble carrier 2 from the amplification liquid filling hole fills the gap between the intermediate member 30 and the insoluble carrier 2, and is introduced into the test region L through the gap. 1 , confirmation area L 2 and amplification indicator region L 3 and gradually permeates into the insoluble carrier 2.

[0108] 9, the first convex deformation portion 12 has two protrusions 12b erected toward the first pot 40 at a position opposite the first pot 40. When a pressing force is applied to the first convex deformation portion 12 to cause it to deform, the two protrusions 12b come into contact with the first pot 40 to move it. The first convex deformation portion 12 has a centrally symmetrical mountain shape, with two protrusions 12b arranged symmetrically with respect to the apex 12a of the mountain shape and formed independently of each other below (on the back side of) the inclined surfaces 12c that sandwich the apex 12a.

[0109] As shown in A of FIG. 9, the first convex deformation portion 12 is formed on the upper case 10 so that the two protrusions 12b are symmetrically positioned with respect to the center of the contact surface of the first pot 40 before deformation. The breakage portion 34 of the intermediate member 30 is located below the sheet member 43 of the first pot 40 as shown by the dashed line in FIG. 9. When a pressing force is applied to the first convex deformation portion 12 and the first pot 40 is deformed, the tips of the two protrusions 12b contact the first pot 40 and gradually move toward the end side, moving the first pot 40. As shown in B of FIG. 9, after the first convex deformation portion 12 is deformed, the distance between the two protrusions 12b is widened and the tips of the two protrusions 12b are located closer to the end side than half the distance from the center to the end of the contact surface of the first pot 40. In this embodiment, two protrusions 12b are provided independently, with a gap between the protrusions 12b (behind the top 12a), and the first convex deformation portion 12 is formed from a flexible material, so that the space between the two protrusions 12b is greatly expanded while pressing down the first pot 40.

[0110] The shape and arrangement of the protrusions 12b are not limited to the above-described form, and for example, before deformation, the two protrusions 12b may be provided at a position closer to the end than half the distance from the center to the end of the contact surface of the first pot 40.

[0111] The first convex deformation portion 12 that moves the first pot 40 has two protrusions 12b, so that the first pot 40 can be pressed evenly at two points, and therefore the first pot 40 can be moved in parallel. The first convex deformation portion 12 is easily deformed by pressing it with a finger or the like, and the first convex deformation portion 12 becomes convex (concave) downward. It is preferable that the concave shape does not return to its original shape after this pressing, and that the state in which the first pot 40 is pressed can be maintained. The first convex deformation portion 12 is configured to press the apex 12a, but the first convex deformation portion 12 can also be deformed in the same way by pressing the slope of the mountain shape due to the elasticity of the first convex deformation portion 12.

[0112] Figure 10 is an oblique view showing the second convex deformation portion 14, and Figure 11 is a cross-sectional end view taken along line VII-VII' in Figure 10, where A in Figure 11 shows the second convex deformation portion 14 before deformation and B in Figure 11 shows the second convex deformation portion 14 after deformation, and also shows the positional relationship with the second pot 45. The second convex deformation portion 14 breaks the sheet member 48 of the second pot 45 when a pressing force is applied. As shown in A of FIG. 11, the second convex deformation portion 14 has one protrusion 14b erected toward the second pot 45 at a position facing the second pot 45. The liquid delivery pad 4 of the test strip 1 is disposed between the second pot 45 and the second pot 45. When a pressing force is applied to the second convex deformation portion 14, the second convex deformation portion 14 is deformed to be convex toward the second pot 45, that is, to be concave when viewed from the outside, and as shown in B of FIG. 11, the protrusion 14b comes into contact with the surface of the liquid delivery pad 4, breaks through the sheet member 48 of the second pot 45, and pushes the liquid delivery pad 4 into the second pot 45. As shown in Figure 11, this second convex deformation portion 14 has a mountain-shaped shape with an apex 14a slightly upstream in a cross section along the upstream-downstream direction, and is configured so that when deformed, the protrusion portion 14b inclines toward the downstream side and breaks through the sheet member 48.

[0113] By this operation, the liquid-delivery pad 4 is immersed in the amplification liquid 46 in the second pot 45, and the second amplification liquid 46 permeates the liquid-delivery pad 4 by capillary action, making it possible to supply the second amplification liquid 46 to the insoluble carrier 2. The second convex deformation portion 14 is also easily deformed into a concave shape by pressing it with a finger, etc. It is preferable that the concave shape does not return to its original shape after pressing, and the liquid delivery pad 4 is configured to be able to maintain the state of being pressed into the second pot 45.

[0114] The present invention realizes high-sensitivity analysis by deforming the first and second convex deformation parts to supply the amplification liquid without using a device connected to a power source, and one embodiment is assumed to be a mode in which the deformation is performed by hand by a person. Therefore, it is preferable to design the amplification liquid so that it does not accidentally leak to the outside, and it is preferable that the first and second convex deformation parts 12, 14 provided on the upper case 10 are integrally formed with the other parts of the upper case 10 without any gaps. It is preferable that the convex deformation parts 12, 14 are made of an expandable material and are joined to the other parts of the upper case 10 in a sealed state. The first and second convex deformation parts 12, 14 of the upper case 10 and the other parts may be made separately and then joined to each other, but it is preferable that the first and second convex deformation parts 12, 14 are integrally molded as a part of the upper case 10 by injection molding as a continuous single member without any joints in between.

[0115] The first and second convex deformation portions 12, 14 must be flexible enough to be easily deformed by a human finger, etc. The flexural modulus of the material constituting the convex deformation portions 12, 14 is preferably 50 MPa or more and 350 MPa or less, and more preferably 70 MPa or more and 150 MPa or less.

[0116] Furthermore, if the upper case 10 and the lower case 20 are simply fitted together when they are assembled, liquid may leak from the gap, so it is preferable that the fitting portions of the upper case 10 and the lower case 20 are also glued in a sealed state. It is preferable to use ultrasonic welding as a method for bonding the upper case 10 and the lower case 20. It is generally known that ultrasonic welding is difficult unless the members to be welded are made of the same material, and a good combination of the upper case / lower case is polyethylene / polyethylene, polypropylene / polypropylene, or ABS (acrylonitrile-butadiene-styrene copolymer) / ABS.

[0117] On the other hand, when the convex deformation parts 12, 14 are integrally formed with the upper case 10, the material constituting the upper case 10 must be flexible. On the other hand, the lower case 20 is preferably rigid in order to fix the test strip 1 and the second pot 45. Specifically, the flexural modulus of the material constituting the upper case 10 is preferably 50 MPa or more and 350 MPa or less, more preferably 70 MPa or more and 150 MPa or less. The flexural modulus of the material constituting the lower case 20 is preferably 500 MPa or more and 900 MPa or less, particularly preferably 650 MPa or more and 750 MPa or less.

[0118] The flexural modulus is a value calculated from the following formula (1) in an environment at a temperature of 20° C. in accordance with the measurement method of ISO 178 standard. For the material to be measured for flexural modulus, a plate-shaped test piece with width b (mm) and thickness h (mm) is prepared and supported by two supports with a distance between the supports of L (mm). A load of F (N) is applied to the center between the supports, and the amount of deflection (mm) in the direction of the load is measured. A deflection-load curve is created with deflection S (mm) on the horizontal axis and load F (N) on the vertical axis. The tangent line at the origin of this curve is found, and its slope ((ΔF / ΔS) where the change in load is ΔF (N) and the change in deflection is ΔS (mm)) is calculated, and the flexural modulus E (MPa) can be calculated using the following formula. Flexural modulus E=(L 3 / (4bh 3 ))×(ΔF / ΔS) Equation (1)

[0119] Therefore, the most preferable combination of upper case / lower case is a combination of softener-containing polypropylene / polypropylene. Here, the softener used in the softener-containing polypropylene is preferably an olefin-based elastomer, and the concentration of the olefin-based elastomer relative to the polypropylene is preferably 20% by mass or more and 60% by mass or less, and particularly preferably 40% by mass or more and 55% by mass or less. A specific example of the softener is Tafthren (registered trademark) manufactured by Sumitomo Chemical Co., Ltd.

[0120] In addition, the immunochromatography kit of the present invention may have two or more convex deformation portions, and if there are three or more types of solutions to be supplied to the test strip, it may also have three or more convex deformation portions accordingly.

[0121] For example, a nitrocellulose membrane can be used as the insoluble carrier 2. The back adhesive sheet 7 to which the insoluble carrier 2 is fixed is a sheet-like substrate having an adhesive surface to which the insoluble carrier 2 is attached.

[0122] The label holding pad 3 is fixed to the center in the longitudinal direction of the insoluble carrier 2. For example, a gold colloid having a diameter of 50 nm (EM.GC50, manufactured by BBI) can be used as the labeling substance. The surface of the labeling substance can be modified with a substance that binds to the test substance to form a conjugate with the test substance. The labeling substance is not limited to the above, and metal sulfides that can be used in normal chromatography, colored particles that can be used in immune agglutination reactions, etc. can be used, and metal colloids are particularly preferred. Metal colloids include gold colloids, silver colloids, platinum colloids, iron colloids, aluminum hydroxide colloids, and composite colloids of these, and in particular, gold colloids are preferred in that they are red and silver colloids are yellow at appropriate particle sizes, and among these, gold colloids are the most preferred.

[0123] The test strip 1 is positioned so that the position of the sample liquid dropping hole 16 of the upper case 10 and the position of the label holding pad 3 coincide with each other.

[0124] Inspection area L 1 The second substance binding region is a labeled substance capture region in which the labeled substance bound to the test substance is captured via the test substance. For example, when influenza A virus or its biomarker is to be detected as the test substance, the test region L is bound to an antibody immobilization line in which an anti-influenza A monoclonal antibody (Anti-Influenza A SPTN-5 7307, manufactured by Medix Biochemica) is immobilized in a line shape by physical adsorption. 1 A preferred embodiment is one in which the above is configured as follows. This inspection area L 1 When the complex of the test substance and the labeling substance bound via the first substance reaches the test area L, the second substance and the test substance specifically bind to each other, and the labeling substance is captured via the test substance and the first substance. On the other hand, the labeling substance that does not form a complex with the test substance is captured in the test area L. 1 It passes through without being supplemented.

[0125] Confirmation area L 2 contains a substance capable of binding to the first substance, and is developed in the insoluble carrier 2 together with the sample liquid from the label holding pad 3, and is deposited in the test area L 1 The labeled substance that has passed through the first substance is captured by the first substance, and the completion of the development of the sample liquid is confirmed. For example, when influenza A virus or its biomarker is to be detected as a test substance, an embodiment in which an anti-mouse IgG antibody (anti-mouse IgG(H+L), rabbit F(ab')2, product number 566-70621, Fujifilm Wako Pure Chemical Industries, Ltd.) is immobilized in a line shape by physical adsorption is preferable.

[0126] Amplification indicator region L 3contains a substance that reacts with the second amplification liquid 46, and reacts with the second amplification liquid 46 to develop color or change color, thereby indicating that the second amplification liquid 46 has been developed up to that region, and serving as an indicator of the timing of dropping the first amplification liquid 41. For example, when a mixed aqueous solution of iron nitrate and citric acid (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd., 038-06925) is used as the second amplification liquid, the amplification indicator region L is indicated by a color-developing reagent immobilization line in which bromocresol green (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) is immobilized in a line shape. 3 In this case, the second amplification solution 46 is preferably configured as the amplification indicator region L 3 When it reaches the region L 3 The color of the test area L changes from green to orange. 1 and confirmation region L 2 This can be taken as an indication that the second amplification liquid 46 has sufficiently filled the cavity.

[0127] A preferred method for amplifying the signal from a metal-based labeling substance such as a metal colloid is to contact the labeling substance with silver ions and a reducing agent for silver ions, reduce the silver ions with the reducing agent to generate silver particles, and deposit the silver particles on the labeling substance using the labeling substance as a nucleus, thereby amplifying the signal from the labeling substance (hereinafter referred to as silver amplification). In order to realize silver amplification, a solution containing silver ions may be used as the first amplification liquid 41, and a reducing agent solution containing a reducing agent for silver ions may be used as the second amplification liquid .

[0128] (First amplification solution) The solution containing silver ions used as the first amplifying liquid 41 is preferably one in which a silver ion-containing compound is dissolved in a solvent. As the silver ion-containing compound, an organic silver salt, an inorganic silver salt, or a silver complex can be used. Preferably, it is an inorganic silver salt or a silver complex. As the inorganic silver salt, it is possible to use a silver ion-containing compound that is highly soluble in a solvent such as water, and examples of such compounds include silver nitrate, silver acetate, silver lactate, silver butyrate, and silver thiosulfate. Silver nitrate is particularly preferred. As the silver complex, a silver complex coordinated to a ligand having a water-soluble group such as a hydroxyl group or a sulfonic group is preferred, and examples of such compounds include silver hydroxythioether.

[0129] (Second amplification solution) The reducing agent used in the reducing agent solution containing a reducing agent capable of reducing silver ions used as the second amplification solution 46 may be any inorganic or organic material or mixture thereof that can reduce silver ions to silver. As the inorganic reducing agent, Fe 2+ , V 2+ Or Ti 3+ Preferred examples of reducing metal salts and reducing metal complexes are those that can change the valence with metal ions such as Fe. When using an inorganic reducing agent, it is necessary to form a complex or reduce the oxidized ions, and remove or render them harmless. For example, Fe 2+ In the system using Fe as a reducing agent, citric acid or EDTA (ethylenediaminetetraacetic acid) is used to reduce the oxide Fe 3+ In this system, it is preferable to use such an inorganic reducing agent, and more preferably Fe 2+ Preferred are metal salts of the formula:

[0130] In addition, developing agents used in wet silver halide photographic light-sensitive materials (e.g., methyl gallate, hydroquinone, substituted hydroquinone, 3-pyrazolidones, p-aminophenols, p-phenylenediamines, hindered phenols, amidoximes, azines, catechols, pyrogallols, ascorbic acid (or its derivatives), and leuco dyes), as well as other materials obvious to those skilled in the art, such as those described in U.S. Pat. No. 6,020,117, can also be used.

[0131] The reducing agent is preferably an ascorbic acid reducing agent. Useful ascorbic acid reducing agents include ascorbic acid and analogs, isomers and derivatives thereof, such as D- or L-ascorbic acid and its sugar derivatives (e.g., γ-lactoascorbic acid, glucoascorbic acid, fucoascorbic acid, glucoheptoascorbic acid, maltoascorbic acid), sodium salt of ascorbic acid, potassium salt of ascorbic acid, isoascorbic acid (or L-erythroascorbic acid), salts thereof (e.g., alkali metal salts, ammonium salts or salts known in the art), enediol type ascorbic acid, enaminol type ascorbic acid, thioenol type ascorbic acid, etc., and particularly D, L or D,L-ascorbic acid (and its alkali metal salts) or isoascorbic acid (or its alkali metal salts), with sodium salts being the preferred salts. If necessary, a mixture of these reducing agents can be used.

[0132] In this embodiment, the first convex deformation portion 12 moves the first pot 40 toward the breaking portion 34 provided in the intermediate member 30, but the first convex deformation portion 12 may be configured to break the sheet member 43 of the first pot 40 by the breaking portion 34 as the first pot 40 deforms.

[0133] The configuration of the first pot 40 and the storage section 32 that stores the first pot 40 is not limited to the configuration of this embodiment, so long as the sheet member 43 of the first pot 40 is broken and the first amplification liquid 41 flowing out from the first pot 40 can be dripped onto the insoluble support 2 through the amplification liquid filling hole on the bottom surface of the storage section 32.

[0134] In addition, it is preferable that the first convex deformation portion has two or more protrusions, so that the first pot 40 can be moved in parallel without tilting. However, the first convex member may have one protrusion having the same shape as the second convex deformation portion of the above embodiment. A convex deformation portion having the same shape as the second convex deformation portion may also be used as the first convex deformation portion that moves the first pot 40.

[0135] FIG. 12 is a cross-sectional end view similar to FIG. 11, showing a form in which a deformation portion 114 having the same shape as the second convex deformation portion is used to move the first pot 40. In FIG. 12A, before deformation, the first pot 40 is positioned below the protrusion 114b of the convex deformation portion 114. In addition, the breakage portion 34 of the intermediate member 30 is positioned below the first pot 40. By pressing down the top 114a of the convex deformation portion 114, the protrusion 114b presses against the upper surface of the first pot 40, and presses down the first pot 40. As a result, the breakage portion 34 breaks through the sheet member 43 of the first pot 40, and the first amplification liquid 41 sealed in the first pot 40 flows out of the first pot and is supplied to the test strip 1. In this way, even if the convex deformation portion 114 has only one protrusion, the pot can be moved.

[0136] The immunochromatography kit of the present invention may also include a set or part of the equipment necessary for the test, such as a pot containing a specimen extract solution containing auxiliary chemicals that aid in specimen extraction, a pot containing a specimen dilution solution, a desiccant or oxygen absorber to aid in preservation of the kit, package inserts such as instruction manuals, and a specimen collection tool such as a cotton swab.

[0137] By using this immunochromatography kit, accurate testing can be performed using the kit alone, without the need for dedicated analytical equipment.

[0138] <Immunochromatography test method> The immunochromatographic testing method using the above-mentioned immunochromatographic kit 100 will be briefly described. The sample liquid is dropped onto the label retention pad 3 through the sample liquid dropping hole 16. When the sample liquid contains a test substance, the test substance and the first substance are bound to each other in the label retention pad 3, forming a complex between the test substance and the label substance via the first substance, and this complex is developed toward the absorbent pad 6 side together with the sample liquid by capillary action due to the suction force of the absorbent pad 6. At the same time as or after dropping the sample liquid, the second convex deformation portion 14 is pressed down, the liquid delivery pad 4 is displaced to break the sheet member 48 of the second pot 45, and the liquid delivery pad 4 is immersed in the second amplification liquid 46 to deliver the second amplification liquid 46 to the insoluble carrier 2. The timing for pressing the second convex deformation portion 14 is preferably within 30 seconds from the time of dropping the sample liquid, and more preferably immediately after dropping the sample liquid.

[0139] Inspection area L 1 The complex that reaches the test area L 1 The first substance that is not bound to the test substance is captured in the test area L 1 Pass through confirmation area L 2 Reach and check area L 2 The first substance binds to the substance that binds to the first substance and is captured.

[0140] The second amplification solution 46 is 1 , confirmation area L 2 Amplification indicator region L 3 At this time, the amplification indicator region L 3 The color of the amplification indicator region L of the second amplification solution 46 changes. 3 It is possible to visually recognize the arrival of the amplification indicator region L 3After confirming the color change of the insoluble carrier 2, the first convex deformation portion 12 is pressed down to supply the first amplification liquid 41 onto the insoluble carrier 2.

[0141] After the first amplification solution 41 is supplied to the insoluble carrier 2, the reaction is awaited to be completed, and the test area L 1 and confirmation region L 2 Check the color development in the test area L 1 The color change in the confirmation area L makes it possible to confirm the presence or absence of the test substance and its concentration. 2 The color change in the test area L can be used to confirm whether the test for measuring the test substance was successful. 1 and confirmation region L 2 The color produced in the assay is obtained by amplifying the label signal, making it possible to realize a highly sensitive test. EXAMPLES

[0142] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples. [A] When the antigen is LAM

[0143] [Preparation of sample solution] Lipoarabinomannan (LAM) (02249-61, Nacalai Tesque) extracted from Mycobacterium tuberculosis (antigen) was added to a pooled urine sample from healthy individuals (Bioreclamation IVT) to prepare a sample solution (liquid that may contain antigen) with a LAM concentration of 0.1 ng / mL.

[0144] [Example A1]

[0145] [Preparation of Concentration Device] The concentrating device of Example A1 was prepared as follows. First, a mini centrifugal filter (VIVACLEAR MINI 0.8 μm, porous membrane material: polyethersulfone (PES), porous membrane pore size: 0.8 μm, manufactured by Sartorius) was prepared. As shown in FIG. 2, the centrifugal filter includes a first container 210 and a second container 220, and the bottom of the first container 210 is configured by a discharge part 212 made of a porous membrane. The surface energy of PES, which is the material of the porous membrane, is 46 dynes / cm. Next, 100 mg of commercially available SAP particles (Aqualic CA, manufactured by Nippon Shokubai Co., Ltd., swelling ratio: 30 g / g, particle size: 300 μm) were placed in the first container of the mini centrifugal filter. In this way, a concentration device as shown in FIG. 1 was obtained.

[0146] [Concentration of sample liquid] Using the obtained concentrating device, the above-mentioned sample liquid was concentrated as follows.

[0147] <Sample liquid injection process> 700 μL of the above-mentioned sample liquid (sample liquid with LAM concentration of 0.1 ng / mL) was injected into the first container of the obtained concentration device and mixed with the SAP particles (Figure 3A). Note that the injected sample liquid was retained in the first container without being discharged from the outlet.

[0148] <Water absorption process> After that, the container was left to stand for 5 minutes. During this time, the SAP particles absorbed the solvent contained in the sample liquid (water, low molecular weight substances), and a sample liquid concentrate was generated in the first container (Figure 3B).

[0149] <Discharge process> Next, the concentration device was placed in a small microcentrifuge (Multi-Spin, manufactured by Tommy Seiko Co., Ltd.), and centrifugal force was applied from top to bottom (towards the discharge part) to the concentrated specimen liquid (rotation speed: 6000 rpm, time: several tens of seconds), and the concentrated specimen liquid was discharged from the porous membrane (discharge part) (Figure 3C).

[0150] <Recovery process> The discharged concentrated specimen liquid was collected in a second container (FIG. 3D). The volume of the concentrated specimen liquid obtained was 100 μL. The concentration time (the time (min) taken from the specimen liquid injection step to the collection step) was 7 minutes.

[0151] [Detection of LAM] The obtained concentrated sample solution (60 μL) was analyzed using a commercially available LAM kit (Alere Determine, manufactured by Alere). TM LAM was detected using TBLAM Ag), and the optical density was then measured using a Fujifilm LAS4000. In addition, aqueous solutions with LAM concentrations of 0.1 ng / mL, 0.2 ng / mL, 0.3 ng / mL, and 0.4 ng / mL were prepared, and the optical density was measured in the same manner to create a calibration curve. Then, for the above-mentioned sample liquid concentrate, the LAM concentration (after concentration) was calculated from the optical density using the calibration curve, and the LAM concentration ratio (=LAM concentration (after concentration) / LAM concentration (before concentration)) was calculated. The LAM concentration ratio is shown in Table 1. When the LAM concentration ratio is greater than 1, it means that the sample liquid is concentrated. A higher LAM concentration ratio is preferable.

[0152] [Example A2] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: cellulose acetate (CA), pore size: 5 μm) (CA membrane removed from Minisalt CA 5 μm manufactured by Advantech) was attached instead. As shown in FIG. 2, the mini centrifugal filter after the porous membrane replacement comprises a first container and a second container, and the bottom of the first container is composed of a porous membrane (discharge section). The surface energy of CA, the material of the porous membrane, is 50 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. Using the obtained concentrating device, the sample liquid was concentrated and LAM was detected in the same manner as in Example A1. The LAM concentration rate is shown in Table 1. The amount of the concentrated specimen liquid obtained was 100 μL, and the concentration time was 7 minutes.

[0153] [Example A3] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: cellulose acetate (CA), pore size: 0.2 μm) (CA membrane removed from Minisalt CA 0.2 μm manufactured by Advantech) was attached instead. As shown in FIG. 2, the mini centrifugal filter after the porous membrane replacement comprises a first container and a second container, and the bottom of the first container is composed of a porous membrane (discharge section). The surface energy of CA, which is the material of the porous membrane, is 50 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. Using the obtained concentrating device, the sample liquid was concentrated and LAM was detected in the same manner as in Example A1. The LAM concentration rate is shown in Table 1. The amount of the concentrated specimen liquid obtained was 100 μL, and the concentration time was 7 minutes.

[0154] [Example A4] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: glass fiber (GF), pore size: 0.45 μm) (GF membrane removed from Pladisc 13 manufactured by Cytiva) was attached instead. As shown in FIG. 2, the mini centrifugal filter after the porous membrane replacement comprises a first container and a second container, and the bottom of the first container is composed of a porous membrane (discharge section). The surface energy of GF, the material of the porous membrane, is 73 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. Using the obtained concentrating device, the sample liquid was concentrated and LAM was detected in the same manner as in Example A1. The LAM concentration rate is shown in Table 1. The amount of the concentrated specimen liquid obtained was 100 μL, and the concentration time was 7 minutes.

[0155] [Example A5] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: hydrophilic PTFE, pore size: 0.05 μm) (PTFE membrane manufactured by Advantech) was attached instead. As shown in FIG. 2, the mini centrifugal filter after the porous membrane replacement comprises a first container and a second container, and the bottom of the first container is composed of a porous membrane (discharge section). The surface energy of the hydrophilic PTFE, which is the material of the porous membrane, is 35 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. Using the obtained concentrating device, the sample liquid was concentrated and LAM was detected in the same manner as in Example A1. The LAM concentration rate is shown in Table 1. The amount of the concentrated specimen liquid obtained was 100 μL, and the concentration time was 7 minutes.

[0156] [Example A6] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: hydrophobic PTFE, pore size: 0.05 μm) (PTFE membrane manufactured by Advantech) was attached instead. As shown in FIG. 2, the mini centrifugal filter after the porous membrane replacement comprises a first container and a second container, and the bottom of the first container is composed of a porous membrane (discharge section). The surface energy of the hydrophobic PTFE, which is the material of the porous membrane, is 23 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. Using the obtained concentrating device, the sample liquid was concentrated and LAM was detected in the same manner as in Example A1. The LAM concentration rate is shown in Table 1. The amount of the obtained concentrated specimen liquid was 60 μL, and the concentration time was 7 minutes. The reason for the small amount of the concentrated specimen liquid obtained is thought to be the small pore size of the porous membrane.

[0157] [Example A7] A concentration device was prepared according to the same procedure as in Example A1. The above-mentioned sample liquid was diluted 4-fold with the pooled urine samples to prepare a sample liquid (liquid that may contain an antigen) with a LAM concentration of 0.025 ng / mL, and the sample liquid was concentrated and LAM was detected in the same manner as in Example A1, except that this sample liquid was used. The LAM concentration rate is shown in Table 1.

[0158] [Comparative Example A1] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: glass fiber (GF), pore size: 100 μm) (GF membrane manufactured by Merck) was attached instead. As shown in FIG. 2, the mini centrifugal filter after the porous membrane replacement comprises a first container and a second container, and the bottom of the first container is constituted by a porous membrane (discharge section). The surface energy of GF, the material of the porous membrane, is 73 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. When the obtained concentration device was used to concentrate the sample liquid in the same manner as in Example A1, the sample liquid injected into the first container was not retained in the first container, but was entirely discharged from the discharge section and collected in the second container. The collected sample liquid was 700 μL. The sample liquid collected in the second container was subjected to LAM detection in the same manner as in Example A1. The LAM concentration rate is shown in Table 1.

[0159] [Comparative example A2] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: cellulose, pore size: less than 0.01 μm) (membrane removed from Merck's Amicon Ultra 3 kDa, 0.5 mL) was attached instead. The mini centrifugal filter after the porous membrane replacement includes a first container and a second container, as shown in FIG. 2, and the bottom of the first container is composed of a porous membrane (discharge section). The surface energy of GF, which is the material of the porous membrane, is 73 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. When the obtained concentrating device was used to concentrate the specimen liquid in the same manner as in Example A1, the concentrated specimen liquid was not discharged from the porous membrane by short-time centrifugation in the discharge step, and the concentrated specimen liquid could not be recovered. Therefore, LAM detection was not performed.

[0160] [Comparative example A3] Instead of the concentrating device of Example A1, a mini centrifugal filter (VIVACLEAR MINI 0.8 μm, porous membrane material: polyethersulfone (PES), porous membrane pore size: 0.8 μm, manufactured by Sartorius) (without SAP particles) was used, and the sample liquid injection step, discharge step, and recovery step were carried out in the same manner as in Example A1. All of the sample liquid injected into the first container was recovered in the second container. The amount of the recovered sample liquid was 700 μL. LAM detection was carried out on the recovered sample liquid in the same manner as in Example A1. The LAM concentration rate is shown in Table 1.

[0161] [Comparative example A4] The above-mentioned sample liquid was concentrated using Amicon Ultra (3k (3k is 3KDa, molecular weight cutoff)) (Merck; UFC5003BK). As shown in Figure 13, this product consists of a filtration membrane unit and a liquid-passing collection container. The product is designed to recover concentrated liquid from the filtration membrane unit by inserting the filtration membrane unit into the liquid-passing collection container (no filtration membrane) and centrifuging it. The method for recovering concentrated liquid remaining in the filtration membrane unit is to insert the filtration membrane unit into the liquid-passing collection container in the opposite direction to that of the initial centrifugation, and then centrifugation is performed at a low rotation speed to recover the concentrated liquid. The filtration membrane used in the filtration membrane unit is manufactured by Millipore and uses a low-adsorption regenerated cellulose membrane. The pore size is not specified, but since the molecular weight cutoff is 3KDa, it is estimated to be 0.05μm or less. There are two liquid collection containers, one of which is a container for collecting and disposing of the liquid that has passed through the filtration membrane unit. The other is a container for collecting the concentrated liquid remaining in the filtration membrane unit. 700 μL of specimen liquid with a LAM concentration of 0.1 ng / mL was placed in the filtration membrane unit of such a product. The unit was inserted into the liquid collection container 1 and centrifuged at 4° C. and 8000 rpm for 20 minutes. At this time, 370 μL of liquid was transferred to the liquid collection container side, and a small amount of liquid remained in the filtration membrane unit. The liquid collection container was replaced with a new container (liquid collection container 2), and the ultrafiltration unit was inserted into the collection container in the opposite direction to the direction of insertion into the collection container in the first centrifugation, and centrifuged at 2000 rpm for 2 minutes (referred to as reverse spin centrifugation). The amount of the specimen liquid concentrate obtained as a result was 130 μL. At this time, the time required for concentration was 26 minutes. The obtained specimen liquid concentrate was subjected to detection of LAM in the same manner as in Example A1. Table 1 shows the LAM concentration rate.

[0162] [Comparative Example A5] The porous membrane (material: PES) was removed from the mini centrifugal filter used in Example A1, and a porous membrane (material: polypropylene (PP), pore size: 50 μm) (fine polypropylene mesh manufactured by AS ONE Corporation) was attached instead. As shown in FIG. 2, the mini centrifugal filter after the porous membrane replacement comprises a first container and a second container, and the bottom of the first container is constituted by the porous membrane (discharge section). The surface energy of GF, the material of the porous membrane, is 73 dynes / cm. Next, 100 mg of commercially available SAP particles (AQUALIC CA manufactured by Nippon Shokubai Co., Ltd.: swelling ratio 30 g / g) was placed in the first container of the mini centrifugal filter after the porous membrane replacement. In this way, a concentration device as shown in FIG. 1 was obtained. When the obtained concentration device was used to concentrate the sample liquid in the same manner as in Example A1, the sample liquid injected into the first container was not retained in the first container, but was discharged from the discharge portion and collected in the second container. The sample liquid collected in the second container was subjected to detection of LAM in the same manner as in Example A1. The LAM concentration rate is shown in Table 1.

[0163] [Reference example A6] A concentration device was prepared according to the same procedure as in Comparative Example A3. The above-mentioned specimen liquid was diluted 4-fold with pooled urine specimens to prepare a specimen liquid (liquid that may contain an antigen) with a LAM concentration of 0.025 ng / mL. Except for using this specimen liquid, the specimen liquid injection step, discharge step, and recovery step were performed in the same manner as in Comparative Example A3. All of the specimen liquid injected into the first container was recovered in the second container. The amount of the recovered specimen liquid was 700 μL. The recovered specimen liquid was subjected to LAM detection in the same manner as in Example A1, but the concentration was below the detection limit and was not confirmed. Since LAM was not concentrated, it is shown as 1x in Table 1.

[0164] [Table 1]

[0165] In Table 1, "SAP swelling ratio" indicates the swelling ratio [g / g] of the superabsorbent polymer used. The method for measuring the swelling ratio is as described above. In Table 1, "porous membrane material" indicates the material of the porous membrane used, PES stands for polyethersulfone, CA stands for cellulose acetate, GF stands for glass fiber, hydrophilic PTFE stands for hydrophilic polytetrafluoroethylene, hydrophobic PTFE stands for hydrophobic polytetrafluoroethylene, and PP stands for polypropylene. In Table 1, "pore size" indicates the pore size [μm] of the porous membrane used. In Table 1, "surface energy" indicates the surface energy [dynes / cm] of the material of the porous membrane used. The method for measuring the surface energy is as described above. In Table 1, "concentration time" indicates the time (minutes) required from the sample liquid injection step to the recovery step. In practice, the concentration time is preferably 20 minutes or less.

[0166] As can be seen from Table 1, when Examples A1 to A7, which are concentrating devices of the present invention, were used, the sample liquid could be concentrated in a short time (20 minutes or less). Among them, Examples A1 to A5 and Example A7, in which the porous membrane was made of a material having a surface energy of 24 dynes / cm or more and 75 dynes / cm or less, showed higher concentration rates. Among them, Examples A1 to A4, in which the porous membrane was made of a material having a surface energy of 40 dynes / cm or more and 75 dynes / cm or less, showed even higher concentration rates.

[0167] On the other hand, in Comparative Examples A1 and A5 in which the pore size of the porous membrane exceeded 10 μm, as described above, the injected specimen liquid was not retained in the first container, and the specimen liquid could not be concentrated. In addition, in Comparative Example A2 in which the pore size of the porous membrane was less than 0.05 μm, the concentrated sample liquid could not be collected as described above. In addition, in Comparative Examples A3 and A6 in which no superabsorbent polymer was included, the sample liquid could not be concentrated.

[0168] In Examples A1 to A5, the concentration ratio was four times higher with a single centrifugation without the need for reverse spin centrifugation and in the short time of seven minutes, whereas in Comparative Example A4, it was found that the concentration ratio was increased to the same level by two centrifugations and the concentration time was more than three times longer. The optical densities obtained using the LAM kit were approximately the same in Examples A1 to A5 and Comparative Example A4, and about 1 / 4 of those were obtained in the measurements of Comparative Example A1 and Example A7. The concentration in Comparative Example A6 was even lower. It was found that by using the kit having the configuration of the present invention, a four-fold increase in detection sensitivity can be achieved with a concentration means that can be operated in a short time.

[0169] [B] When the antigen is influenza virus

[0170] [Preparation of sample solution] A sample solution (a solution that may contain antigens) was prepared using Quick S-Influenza A·B "Seiken" negative / positive control solution (product number: 322968, Denka Seiken Co., Ltd.). Specifically, the above control solution was diluted with PBS (Phosphate buffered salts) buffer containing 0.1% by mass BSA (Bovine Serum Albumin) to prepare specimen solutions (liquids that may contain antigens) of various concentrations. Here, the concentration (fold) is the control solution / (control solution+buffer), and for example, when the control solution is diluted 100-fold with buffer, the concentration is 0.01-fold.

[0171] [Development of immunochromatographic kit for influenza virus detection] As described below, an immunochromatography kit (detection device) for detecting influenza virus was prepared for detecting influenza virus as a test substance (polymer contained in a biological fluid).

[0172] (1-1) Preparation of anti-influenza A antibody-modified gold colloid as a labeling substance modified with a first substance capable of binding to a test substance A solution containing 50 nm gold colloids (product number: EM.GC50, manufactured by BBI) was added to 9 mL of 50 mmol / L KH 2 PO 4 The pH was adjusted by adding 1 mL of a buffer (pH 7.5), and then 1 mL of a solution containing 160 μg / mL of an anti-influenza A type monoclonal antibody (Anti-Influenza A SPTN-5 7307, manufactured by Medix Biochemica) was added and stirred for 10 minutes. After leaving it to stand for 10 minutes, 550 μL of an aqueous solution containing 1% by mass of polyethylene glycol (PEG (polyethylene glycol); weight average molecular weight (Mw.): 20000, product number: 168-11285, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) was added and stirred for 10 minutes, and then 1.1 mL of an aqueous solution of 10% by mass of bovine serum albumin (BSA (Bovine serum albumin); Fraction V, product number: A-7906, manufactured by SIGMA) was added and stirred for 10 minutes. This solution was centrifuged at 8000×g and 4°C for 30 minutes using a centrifuge (himacCF16RX, Hitachi, Ltd.). The supernatant was removed leaving 1 mL at the bottom of the container, and the gold colloid contained in the 1 mL of the solution remaining at the bottom of the container was redispersed using an ultrasonic cleaner. After this, it was dispersed in 20 mL of gold colloid storage solution (20 mmol / L Tris-HCl (Tris hydrochloric acid) buffer (pH 8.2), 0.05% PEG (Mw. 20000), 150 mmol / L NaCl, 1% BSA), and centrifuged again under the same conditions using the same centrifuge, the supernatant was removed, and after ultrasonic dispersion, it was dispersed in gold colloid storage solution to obtain an anti-influenza A antibody-modified gold colloid (50 nm) solution.

[0173] (1-2) Preparation of anti-influenza A antibody-modified gold colloid holding pad as a label holding pad The anti-influenza A antibody-modified gold colloid prepared in (1-1) was diluted with water to a Tris-HCl buffer (pH 8.2) concentration of 20 mmol / L, PEG (Mw. 20000) concentration of 0.05 mass%, sucrose concentration of 5 mass%, and an optical path length of 10 mm, so that the optical density of the gold colloid at 520 nm was 0.1, to prepare a gold colloid coating solution. 0.8 mL of this coating solution was evenly applied to a glass fiber pad (Glass Fiber Conjugate Pad, Millipore) cut to 12 mm x 300 mm, and dried under reduced pressure for 24 hours to obtain an anti-influenza A antibody-modified gold colloid-retaining pad (gold colloid-retaining pad).

[0174] (1-3) Preparation of chromatographic support A nitrocellulose membrane (with plastic lining, HiFlow Plus HF135 (capillary flow rate = 135 sec / cm), manufactured by Millipore) cut to 60 mm x 300 mm was used as an insoluble carrier, and a chromatographic carrier was prepared by forming a test area, a confirmation area, and an amplification indicator area on this membrane using the following method.

[0175] A solution of anti-influenza A monoclonal antibody (Anti-Influenza A SPTN-5 7307, manufactured by Medix Biochemica) prepared at 1.5 mg / mL was applied in a line shape to a position 15 mm from the downstream side of the 60 mm short side of the nitrocellulose membrane to form a test area. Furthermore, a solution of anti-mouse IgG antibody (anti-mouse IgG (H+L), rabbit F(ab')2, product number 566-70621, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) prepared at 0.2 mg / mL was applied in a line shape to a position 11 mm from the downstream side of the 60 mm short side to form a confirmation area. Furthermore, a solution of bromocresol green (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) prepared at 30 mmol / L was applied in a line shape to a position 9 mm from the downstream side of the 60 mm short side to form an amplification indicator area. After each application, the nitrocellulose membrane was dried in a hot air dryer at 50 ° C. for 30 minutes. After drying, the nitrocellulose membrane dried as described above was immersed in a tray containing 500 mL of blocking solution (50 mmol / L borate buffer (pH 8.5) containing 0.5% by mass casein (derived from milk, product number 030-01505, Fujifilm Wako Pure Chemical Industries, Ltd.)) and left to stand for 30 minutes. The nitrocellulose membrane was then removed and immersed in 500 mL of washing and stabilizing solution (50 mmol / L Tris-HCl (pH 7.5) buffer containing 0.5% by mass sucrose and 0.05% by mass sodium cholate) prepared in a separate tray and left to stand for 30 minutes. The nitrocellulose membrane was then removed from the solution and dried in an environment of 25°C for 24 hours.

[0176] The area where the anti-influenza A antibody is immobilized corresponds to the test area containing a second substance that binds to the test substance, the area where the anti-mouse IgG antibody is immobilized corresponds to the confirmation area containing a substance capable of binding to the first substance, and the area where the bromocresol green is immobilized corresponds to the amplification indicator area containing a substance that reacts with the second amplification solution, which is a reducing agent solution to be sealed in the second pot, as described below.

[0177] (1-4) Preparation of test strips The chromatography carrier prepared in (1-3) was attached to a back adhesive sheet (60 mm x 300 mm (manufactured by Nippon Techno Cluster Co., Ltd.)). Next, 3 mm-wide double-sided tape (Nitto Denko) was fixed to a position 26 mm from the downstream side of the short side of the chromatography carrier. After that, the gold colloid retention pad prepared in (1-2) was fixed to the chromatography carrier so that the downstream end of the double-sided tape and the downstream end of the gold colloid retention pad were overlapped. A liquid delivery pad (a glass fiber pad cut to 25 mm x 300 mm (Glass Fiber Conjugate Pad, manufactured by Millipore Co., Ltd.)) was attached to the upstream side of the chromatography carrier so that the liquid delivery pad and the chromatography carrier overlapped by 7 mm. The thus-prepared member was cut parallel to the direction perpendicular to the 300 mm long side with a guillotine cutter (CM4000, manufactured by Nippon Techno Cluster Co., Ltd.) to a width of 5 mm to prepare 60 test strips (excluding absorbent pads).

[0178] (1-5) Preparation of amplification solution (1-5-1) Preparation of amplification solution (reducing agent solution) to be sealed in the second pot In 290 g of water, 23.6 mL of a 1 mol / L aqueous solution of iron nitrate (Fujifilm Wako Pure Chemical Industries, Ltd., 095-00995) was dissolved in water, and 13.1 g of citric acid (Fujifilm Wako Pure Chemical Industries, Ltd., 038-06925) was dissolved. After all of the solution was dissolved, 36 mL of a nitric acid (10 wt%) solution was added while stirring with a stirrer, and 60.8 g of ammonium iron (II) sulfate hexahydrate (Fujifilm Wako Pure Chemical Industries, Ltd., 091-00855) was added. The solution prepared in this way was used as a reducing agent solution, which is the second amplification solution to be sealed in the second pot.

[0179] (1-5-2) Preparation of amplification solution (silver ion solution) to be sealed in the first pot To 66 g of water, 8 mL of silver nitrate solution (containing 10 g of silver nitrate) and 24 mL of 1 mol / L aqueous iron nitrate solution were added. This solution, 5.9 mL of nitric acid (10 wt%), 0.1 g of dodecylamine (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., 123-00246), and surfactant C were added. 12 H25 -C 6 H 4 -O-(CH 2 CH 2 O) 50 A solution in which 0.1 g of H had been dissolved in 47.6 g of water was mixed, and this was used as the silver ion solution, which was the first amplification solution to be sealed in the first pot.

[0180] (1-6) Preparation of absorbent pads Sixty pieces of glass fiber pads (glass filter paper, manufactured by Advantec Co., Ltd.) cut to 12 mm x 10 mm were prepared as absorbent pads.

[0181] (1-7) Preparation of immunochromatography kit components The lower case 20, the upper case 10, the intermediate member 30, the first pot 40, and the second pot 45 constituting the immunochromatography kit 100 as shown in Figures 5 and 6 were each produced by injection molding using polypropylene. It was produced by injection molding using polypropylene containing 50% by mass of Tafthren (registered trademark), an olefin-based elastomer manufactured by Co., Ltd. The upper case 10 has two deformable portions (a first convex deformation portion and a second convex deformation portion), and these two deformation portions are not separated from the upper case 10, and all of the boundaries are produced by injection molding as part of the upper case 10. The upper case had a configuration in which the first convex deformation portion 12 had two protrusions and the second convex deformation portion 14 had one protrusion as shown in Figures 5 and 6. The flexural moduli of the materials of the upper case and the lower case were 90 (MPa) and 700 (MPa), respectively.

[0182] (1-8) Preparation of immunochromatography kit The lower case 20, the test strip 1 prepared in (1-4), and the absorbent pad 6 prepared in (1-6) were fixed as shown in Fig. 5 and Fig. 6. Next, the first pot 40 and the second pot 45 were filled with the first amplification liquid 41 to be sealed in the first pot 40 and the second amplification liquid 46 to be sealed in the second pot 45, which were prepared in (1-5-2) and (1-5-1), respectively, and the second pot 45 was sealed with aluminum foil as the sheet member 48 and the first pot 40 was sealed with aluminum foil as the sheet member 43, respectively. As shown in Fig. 5 and Fig. 6, the second pot 45 was attached to the lower case 20 with the sheet member 48 facing up, and the first pot 40 was attached to the intermediate member 30 with the sheet member 43 facing down. Then, in a state in which the upper case 10 and the lower case 20 were fitted together so that their outer circumferences were in contact with each other, the contact portions of the upper case and the lower case were joined by ultrasonic welding. At this time, it was confirmed that the welded portions were uniformly welded in a sealed state at all portions. In this manner, an immunochromatography kit for influenza virus detection was produced.

[0183] [Example B1]

[0184] [Preparation of Concentration Device] A concentration device was prepared according to the same procedure as in Example A1.

[0185] [Concentration of sample liquid] Using the obtained concentrating device, the above-mentioned specimen liquid (specimen liquid containing influenza virus) was concentrated according to the same procedure as in Example A1 described above. Specifically, the specimen liquid (specimen liquid containing influenza virus) was concentrated according to the same procedure as in Example A1 described above, except that 700 μL of specimen liquid (specimen liquid containing LAM) was used instead of 700 μL of specimen liquid (specimen liquid containing LAM) in the specimen liquid injection step. The volume of the obtained concentrated specimen liquid was 100 μL. The concentration time (the time (min) taken from the specimen liquid injection step to the recovery step) was 7 minutes.

[0186] [Detection of influenza virus] The obtained concentrated specimen liquid was subjected to influenza virus detection as follows.

[0187] (2-1) Dripping The obtained sample liquid concentrate (40 μL) was dropped onto the gold colloid holding pad of the influenza virus detection immunochromatography kit prepared as described above. This resulted in the formation of a gold particle complex, which is a complex between the influenza A virus in the sample liquid and the gold colloid particles (modified gold particles) in the gold colloid holding pad modified with influenza A monoclonal antibodies. In this state, the gold particle complex was developed on the downstream side of the nitrocellulose membrane.

[0188] (2-2) Development of the amplification solution (reducing agent solution) to be sealed in the second pot Immediately after dripping the sample liquid concentrate (2-1), the second convex deformation portion 14 was pressed down to break the aluminum foil sheet member 48 sealing the second amplification liquid 46 enclosed in the second pot 45, and the liquid delivery pad 4 was immersed in the second pot 45, thereby utilizing capillary action to supply the second amplification liquid 46 to the insoluble carrier 2.

[0189] (2-3) Silver amplification Amplification indicator region L 3 After the color of the first pot 40 changes from green to orange, the first convex deformation portion 12 (first convex deformation portion 114 in Example 2) is pressed down to move the first pot 40 toward the breaking portion 34 of the pot storage portion 32 of the intermediate member 30, whereby the aluminum foil serving as the sheet member 43 sealing the first pot 40 is broken by the breaking portion 34, and the silver ion solution serving as the first amplification liquid 41 is supplied to the insoluble carrier 2 from the opening of the intermediate member 30, thereby carrying out a silver amplification reaction. The silver amplification reaction is completed in several tens of seconds.

[0190] (2-4) Evaluation of concentration rate Inspection area L 1The coloring of the sample was visually confirmed, and the smallest concentration (C1) at which coloring was confirmed was found to be 0.01 times. Furthermore, influenza virus detection was performed in the same manner without concentrating the sample liquid, and the smallest concentration (C0) at which coloring was confirmed was found to be 0.04 times. Here, since the reciprocal of the concentration (C1) is roughly proportional to the concentration rate, the concentration rate was calculated by dividing the reciprocal of C1 by the reciprocal of C0. The results are shown in Table 2. A concentration rate of more than 1 means that the sample liquid is concentrated. A higher concentration rate is preferable.

[0191] [Example B2] A concentration device was prepared according to the same procedure as in Example A1, except that SAP Spheres (manufactured by M2 Polymer Technologies, Inc., swelling ratio: 20 g / g) were used as the SAP particles. Using the obtained concentration device, the sample liquid was concentrated and influenza virus was detected in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.01 times. The concentration ratio is shown in Table 2. The amount of the concentrated specimen liquid obtained was 40 μL, and the concentration time was 4 minutes.

[0192] [Example B3] A concentration device was prepared according to the same procedure as in Example A3. Using the obtained concentration device, the sample liquid was concentrated and influenza virus was detected in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.01 times. The concentration ratio is shown in Table 2.

[0193] [Example B4] A concentration device was prepared according to the same procedure as in Example A4. Using the obtained concentration device, the sample liquid was concentrated and influenza virus was detected in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.01 times. The concentration ratio is shown in Table 2.

[0194] [Example B5] A concentration device was prepared according to the same procedure as in Example A5. Using the obtained concentration device, the sample liquid was concentrated and influenza virus was detected in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.012 times. The concentration ratio is shown in Table 2.

[0195] [Example B6] A concentration device was prepared according to the same procedure as in Example A6. Using the obtained concentration device, the sample liquid was concentrated and influenza virus was detected in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.01 times. The concentration ratio is shown in Table 2.

[0196] [Example B7] A concentration device was prepared according to the same procedure as in Example A1, except that commercially available SAP (super absorbent polymer) particles (model number 197-12451: manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) that had been sized (particle size: 0.05 mm, swelling ratio: 600 g / g, water absorption rate: 20 g / min) were used as the SAP particles. Using the obtained concentration device, the sample liquid was concentrated and influenza virus was detected in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.02 times. The concentration ratio is shown in Table 2.

[0197] [Example B8] A concentration device was prepared according to the same procedure as in Example A1, except that commercially available SAP (super absorbent polymer) particles (SAP Sphere 2.5 mm, manufactured by M2 Polymer Technologies Inc.) were used as the SAP particles (particle size: 2.5 mm, swelling ratio: 13 g / g, water absorption rate: 0.5 g / min). Using the obtained concentration device, the sample liquid was concentrated and influenza virus was detected in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.01 times. The concentration ratio is shown in Table 2.

[0198] [Comparative Example B1] A concentration device was prepared according to the same procedure as in Comparative Example A1. When the obtained concentrating device was used to concentrate the specimen liquid in the same manner as in Example B1, the specimen liquid injected into the first container was not retained in the first container, but was entirely discharged from the discharge section and collected in the second container. The collected specimen liquid was 700 μL. Influenza virus was detected from the specimen liquid collected in the second container in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.04 times. The concentration ratio is shown in Table 2.

[0199] [Comparative example B2] A concentration device was prepared following the same procedure as in Comparative Example A2. When the obtained concentrating device was used to concentrate the specimen liquid in the same manner as in Example B1, the concentrated specimen liquid was not discharged from the porous membrane by short-time centrifugation in the discharge step, and the concentrated specimen liquid could not be collected. Therefore, influenza virus detection was not performed.

[0200] [Comparative Example B3] Instead of the concentrating device of Example B1, a mini centrifugal filter (VIVACLEAR MINI 0.8 μm, porous membrane material: polyethersulfone (PES), porous membrane pore size: 0.8 μm, manufactured by Sartorius) (without SAP particles) was used, and the sample liquid injection step, discharge step, and recovery step were carried out in the same manner as in Example B1. All of the sample liquid injected into the first container was recovered in the second container. The amount of the recovered sample liquid was 700 μL. Influenza virus detection was carried out on the recovered sample liquid in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.04 times. The concentration ratio is shown in Table 2.

[0201] [Comparative example B4] The above-mentioned sample liquid was concentrated using Amicon Ultra (3k (3k is 3KDa, molecular weight cutoff)) (Merck; UFC5003BK). As shown in Figure 13, this product consists of a filtration membrane unit and a liquid-passing collection container. The product is designed to recover concentrated liquid from the filtration membrane unit by inserting the filtration membrane unit into the liquid-passing collection container (no filtration membrane) and centrifuging it. The method for recovering concentrated liquid remaining in the filtration membrane unit is to insert the filtration membrane unit into the liquid-passing collection container in the opposite direction to that of the initial centrifugation, and then centrifugation is performed at a low rotation speed to recover the concentrated liquid. The filtration membrane used in the filtration membrane unit is manufactured by Millipore and uses a low-adsorption regenerated cellulose membrane. The pore size is not specified, but since the molecular weight cutoff is 3KDa, it is estimated to be 0.05μm or less. There are two liquid collection containers, one of which is a container for collecting and disposing of the liquid that has passed through the filtration membrane unit. The other is a container for collecting the concentrated liquid remaining in the filtration membrane unit. 700 μL of specimen liquid was put into the filtration membrane unit of such a product. The unit was inserted into the liquid collection container 1 and centrifuged at 4° C. and 8000 rpm for 20 minutes. At this time, 370 μL of liquid was transferred to the liquid collection container side, and a small amount of liquid remained in the filtration membrane unit. The liquid collection container was replaced with a new container (liquid collection container 2), and the ultrafiltration unit was inserted into the collection container in the opposite direction to the direction of insertion into the collection container in the first centrifugation, and centrifuged at 2000 rpm for 2 minutes (referred to as reverse spin centrifugation). The amount of specimen liquid concentrate obtained as a result was 130 μL. At this time, the time required for concentration was 26 minutes. The specimen liquid concentrate obtained was subjected to influenza virus detection in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.015 times. The concentration rate is shown in Table 2.

[0202] [Comparative Example B5] A concentration device was prepared according to the same procedure as in Comparative Example A5. When the obtained concentrating device was used to concentrate the specimen liquid in the same manner as in Example B1, the specimen liquid injected into the first container was not retained in the first container, but was entirely discharged from the discharge section and collected in the second container. The collected specimen liquid was 700 μL. Influenza virus was detected from the specimen liquid collected in the second container in the same manner as in Example B1. The smallest concentration (C1) at which coloring was confirmed was 0.04 times. The concentration ratio is shown in Table 2.

[0203] [Table 2]

[0204] In Table 2, "SAP swelling ratio" indicates the swelling ratio [g / g] of the superabsorbent polymer used. The method for measuring the swelling ratio is as described above. In Table 2, "porous membrane material" indicates the material of the porous membrane used, PES stands for polyethersulfone, CA stands for cellulose acetate, GF stands for glass fiber, hydrophilic PTFE stands for hydrophilic polytetrafluoroethylene, hydrophobic PTFE stands for hydrophobic polytetrafluoroethylene, and PP stands for polypropylene. In Table 2, "pore size" indicates the pore size [μm] of the porous membrane used. In Table 2, "surface energy" indicates the surface energy [dynes / cm] of the material of the porous membrane used. The method for measuring the surface energy is as described above. In Table 2, "concentration time" indicates the time (minutes) required from the sample liquid injection step to the recovery step. In practice, the concentration time is preferably 20 minutes or less. In Table 2, "sample concentration with minimum detection sensitivity" refers to the above-mentioned "smallest concentration at which coloration was confirmed."

[0205] As can be seen from Table 2, when the concentrating devices of the present invention, Examples B1 to B8, were used, the sample liquid could be concentrated in a short time (20 minutes or less). Comparing Examples B1 to B6 (comparison of embodiments in which only the porous membrane is different), Examples B1 to B5 in which the porous membrane is made of a material having a surface energy of 24 dynes / cm to 75 dynes / cm showed higher concentration ratios, and Examples B1 to B4 in which the porous membrane is made of a material having a surface energy of 40 dynes / cm to 75 dynes / cm showed even higher concentration ratios. In addition, comparing Examples B1 and B7 to B8 (comparisons between embodiments in which only the superabsorbent polymer is different), Examples B1 and B8 in which the swelling ratio of the superabsorbent polymer is 500 g / g or less showed a higher concentration ratio.

[0206] On the other hand, in Comparative Example B1 and Comparative Example B5, in which the pore size of the porous membrane exceeds 10 μm, the injected specimen liquid was not retained in the first container, and the specimen liquid could not be concentrated, as described above. In Comparative Example B2, in which the pore size of the porous membrane is less than 0.05 μm, the specimen liquid concentrate could not be recovered, as described above. In Comparative Example B3, which does not have a superabsorbent polymer, the specimen liquid could not be concentrated. [Explanation of symbols]

[0207] 1 test strip 2. Insoluble Carriers 3 Sign Retaining Pads 4 Fluid transfer pad 6 Absorbent Pads 7 Back adhesive sheet 9 Housing Case 10 Upper Case 12 First convex deformation portion 12a: the top of the first convex deformation portion 12b: protrusion of first convex deformation portion 12c Slope of the first convex deformation 14 Second convex deformation portion 14a: Top of the second convex deformation 14b: protrusion of second convex deformation portion 16 Hole for dropping sample liquid 18 Observation window 20 Lower case 21 Insoluble carrier storage section 22 Absorbent pad storage section 24 Second pot housing 30 Intermediate parts 32 First pot housing 34 Breaking part 35 Flow path forming section 36 Back surface of flow path forming portion 35 First pot for amplification solution 40 1 41 First amplification solution 42 Pot Container 43 Sheet material 45 Second pot for second amplification solution 46 Second Amplifier 47 Pot Container 48 Sheet material 100 Immunochromatography Kit 114 Convex deformation part 114a: the top of the convex deformation portion 114 114b: protrusion of convex deformation portion 114 200, 201, 202, 203, 204 Concentration devices 200a Mini Centrifugal Filter 210 First Container 211 Opening 212 Discharge section 220 Second Container 221 Opening 230 Superabsorbent Polymer 232 Swollen superabsorbent polymer 240 Sample Liquid 242 Sample Liquid Concentrate 300 Nitrocellulose Membrane 301 Gold colloid holding pad 302 Test Line 303 Control Line 304 Color Reagent Fixation Line

Claims

1. A concentrating device for concentrating a specimen liquid, which is an aqueous solution containing a macromolecule contained in a biological fluid, and recovering the specimen liquid by using centrifugal force, comprising: The present invention provides a method for manufacturing a water-absorbent device, comprising: a part of the first container is constituted by a discharge part made of a porous membrane having a pore size of 0.05 μm or more and 10 μm or less, the porous membrane being made of a material having a surface energy of 24 dynes / cm or more and 75 dynes / cm or less; the superabsorbent polymer absorbs a solution contained in the sample liquid poured into the first container, and generates a sample liquid concentrate in the first container, which is a concentrated solution of the sample liquid; A concentrating device, wherein the second container collects the concentrated sample liquid discharged from the discharge portion by centrifugal force.

2. The concentrating device according to claim 1 , wherein the material of the porous membrane is at least one selected from the group consisting of cellulose acetate, polyethersulfone, and glass fiber.

3. The concentrating device according to claim 1 or 2, wherein the porous membrane is made of a material having a surface energy of 40 dynes / cm or more and 75 dynes / cm or less.

4. The concentrating device according to any one of claims 1 to 3, wherein the swelling ratio of the highly absorbent polymer is 20 g / g or more and less than 800 g / g.

5. The concentrating device according to any one of claims 1 to 4, wherein the highly water-absorbent polymer is a polyacrylic acid-based, polyacrylamide-based, cellulose-based, or polyethylene oxide-based polymer.

6. The concentrating device according to any one of claims 1 to 5, wherein the macromolecule contained in the biological fluid is an antigen.

7. The concentrating device according to any one of claims 1 to 6, wherein the sample liquid is urine.

8. The concentrating device according to claim 7 , wherein the concentration of urea in the sample fluid concentrate is 5 times or less the concentration of urea in the sample fluid.

9. A method for concentrating a specimen liquid, comprising the steps of: concentrating a specimen liquid, which is an aqueous solution containing a polymer contained in a biological fluid, using the concentrating device according to any one of claims 1 to 8, a sample liquid injection step of injecting the sample liquid into the first container; a water absorption step in which a solution contained in the specimen liquid injected into the first container is absorbed by a highly water-absorbent polymer contained in the first container, thereby producing a specimen liquid concentrate in the first container, which is a concentrate of the specimen liquid; a discharge step of discharging the specimen liquid concentrate from the discharge portion by applying a centrifugal force to the specimen liquid concentrate; and a recovery step of recovering the concentrated sample liquid discharged from the discharge portion into the second container, in this order.

10. 10. The method for concentrating a specimen liquid according to claim 9, wherein the centrifugal force is applied under conditions of 4,000 to 10,000 revolutions per minute.

11. A method for testing a specimen liquid, comprising the steps of: detecting a polymer contained in the specimen liquid, the polymer being an aqueous solution containing the polymer; A concentrating step of obtaining the sample liquid concentrate by using the method for concentrating a sample liquid according to claim 9 or 10; a detection step of detecting a polymer contained in the biological fluid in the obtained concentrated specimen fluid, in this order.

12. the sample liquid is an aqueous solution that may contain an antigen, The concentrating step is a step of concentrating an aqueous solution that may contain the antigen by using the method for concentrating a specimen liquid according to claim 9 or 10 to obtain an antigen concentrated liquid, The testing method according to claim 11 , wherein the detection step is a step of detecting the antigen in the antigen concentrated solution by immunochromatography using an antigen-antibody reaction.

13. A test kit for detecting a polymer contained in a biological fluid in a sample solution which is an aqueous solution containing a polymer contained in the biological fluid, comprising: A concentrating device according to any one of claims 1 to 8, a detection device comprising: a test strip having a test area for detecting a polymer contained in the biological fluid; a first pot and a second pot in which a first amplification liquid and a second amplification liquid for amplifying a test signal in the test area are sealed, respectively; and a housing case that contains the test strip, the first pot, and the second pot; A test kit comprising:

Citation Information

Patent Citations

  • Water-absorptive resin for living body fluid condensation, its production, and use thereof

    JP2000072822A

  • Methods and devices for processing, labeling and concentrating analytes

    JP2008506930A

  • Concentration and lyophilization of influenza vaccine antigens

    JP2013527225A

  • Method and device for enriching target compounds

    JP2013543110A

  • Method for the concentration and purification of biological compounds

    US7833796B2